<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ep-patent-document PUBLIC "-//EPO//EP PATENT DOCUMENT 1.5.1//EN" "ep-patent-document-v1-5-1.dtd">
<!-- This XML data has been generated under the supervision of the European Patent Office -->
<ep-patent-document id="EP16802989B1" file="EP16802989NWB1.xml" lang="en" country="EP" doc-number="3305912" kind="B1" date-publ="20211006" status="n" dtd-version="ep-patent-document-v1-5-1">
<SDOBI lang="en"><B000><eptags><B001EP>ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESILTLVFIROMKCYALTRBGCZEEHUPLSK..HRIS..MTNORS..SM..................</B001EP><B005EP>J</B005EP><B007EP>BDM Ver 2.0.12 (4th of August) -  2100000/0</B007EP></eptags></B000><B100><B110>3305912</B110><B120><B121>EUROPEAN PATENT SPECIFICATION</B121></B120><B130>B1</B130><B140><date>20211006</date></B140><B190>EP</B190></B100><B200><B210>16802989.0</B210><B220><date>20160510</date></B220><B240><B241><date>20171024</date></B241><B242><date>20181128</date></B242></B240><B250>ja</B250><B251EP>en</B251EP><B260>en</B260></B200><B300><B310>2015113979</B310><B320><date>20150604</date></B320><B330><ctry>JP</ctry></B330></B300><B400><B405><date>20211006</date><bnum>202140</bnum></B405><B430><date>20180411</date><bnum>201815</bnum></B430><B450><date>20211006</date><bnum>202140</bnum></B450><B452EP><date>20210430</date></B452EP></B400><B500><B510EP><classification-ipcr sequence="1"><text>C12Q   1/68        20180101AFI20180205BHEP        </text></classification-ipcr><classification-ipcr sequence="2"><text>C12N  15/09        20060101ALI20180205BHEP        </text></classification-ipcr><classification-ipcr sequence="3"><text>C12Q   1/6816      20180101ALI20180205BHEP        </text></classification-ipcr></B510EP><B520EP><classifications-cpc><classification-cpc sequence="1"><text>C12Q   1/6816      20130101 FI20180130BHEP        </text></classification-cpc><classification-cpc sequence="2"><text>C12Q   1/689       20130101 LI20180607BHEP        </text></classification-cpc></classifications-cpc></B520EP><B540><B541>de</B541><B542>NACHWEISKIT ZUR GLEICHZEITIGEN DETEKTION MEHRERER SICH UNTERSCHEIDENDER ZIELNUKLEINSÄUREN UND NACHWEISVERFAHREN MIT VERWENDUNG DAVON</B542><B541>en</B541><B542>KIT FOR TOGETHER DETECTING MULTIPLE TARGET NUCLEIC ACIDS DIFFERING FROM EACH OTHER AND DETECTION METHOD USING THE SAME</B542><B541>fr</B541><B542>KIT DE DÉTECTION SIMULTANÉE DE MULTIPLE ACIDES NUCLÉIQUES CIBLES DISTINCTS ENTRE EUX ET PROCÉDÉ DE DÉTECTION UTILISANT CELUI-CI</B542></B540><B560><B561><text>EP-A1- 1 411 133</text></B561><B561><text>EP-A1- 2 116 614</text></B561><B561><text>EP-A1- 2 787 077</text></B561><B561><text>WO-A1-2010/068576</text></B561><B561><text>WO-A1-2013/065574</text></B561><B561><text>CN-A- 101 624 629</text></B561><B561><text>JP-A- 2010 207 220</text></B561><B561><text>JP-A- 2012 511 328</text></B561><B561><text>JP-A- 2012 513 215</text></B561><B561><text>JP-A- 2013 000 060</text></B561><B561><text>JP-A- 2014 501 533</text></B561><B561><text>US-A1- 2005 053 950</text></B561><B565EP><date>20180209</date></B565EP></B560></B500><B700><B720><B721><snm>NAGANO, Takashi</snm><adr><str>c/o MIZUHO MEDY CO., LTD.
5-4, Fujinoki-chou</str><city>Tosu-shi, Saga 8410048</city><ctry>JP</ctry></adr></B721><B721><snm>MIYAJIMA, Kensuke</snm><adr><str>c/o MIZUHO MEDY CO., LTD.
5-4, Fujinoki-chou</str><city>Tosu-shi, Saga 8410048</city><ctry>JP</ctry></adr></B721><B721><snm>NARAHARA, Kenji</snm><adr><str>c/o MIZUHO MEDY CO., LTD.
5-4, Fujinoki-chou</str><city>Tosu-shi, Saga 8410048</city><ctry>JP</ctry></adr></B721></B720><B730><B731><snm>MIZUHO MEDY CO., LTD.</snm><iid>101913596</iid><irf>MM6102P--WOEP</irf><adr><str>5-4, Fujinoki-chou</str><city>Tosu-shi
Saga 8410048</city><ctry>JP</ctry></adr></B731></B730><B740><B741><snm>Winter, Brandl - Partnerschaft mbB</snm><iid>100059963</iid><adr><str>Alois-Steinecker-Straße 22</str><city>85354 Freising</city><ctry>DE</ctry></adr></B741></B740></B700><B800><B840><ctry>AL</ctry><ctry>AT</ctry><ctry>BE</ctry><ctry>BG</ctry><ctry>CH</ctry><ctry>CY</ctry><ctry>CZ</ctry><ctry>DE</ctry><ctry>DK</ctry><ctry>EE</ctry><ctry>ES</ctry><ctry>FI</ctry><ctry>FR</ctry><ctry>GB</ctry><ctry>GR</ctry><ctry>HR</ctry><ctry>HU</ctry><ctry>IE</ctry><ctry>IS</ctry><ctry>IT</ctry><ctry>LI</ctry><ctry>LT</ctry><ctry>LU</ctry><ctry>LV</ctry><ctry>MC</ctry><ctry>MK</ctry><ctry>MT</ctry><ctry>NL</ctry><ctry>NO</ctry><ctry>PL</ctry><ctry>PT</ctry><ctry>RO</ctry><ctry>RS</ctry><ctry>SE</ctry><ctry>SI</ctry><ctry>SK</ctry><ctry>SM</ctry><ctry>TR</ctry></B840><B860><B861><dnum><anum>JP2016063831</anum></dnum><date>20160510</date></B861><B862>ja</B862></B860><B870><B871><dnum><pnum>WO2016194552</pnum></dnum><date>20161208</date><bnum>201649</bnum></B871></B870></B800></SDOBI>
<description id="desc" lang="en"><!-- EPO <DP n="1"> -->
<heading id="h0001">BACKGROUND OF THE INVENTION</heading>
<heading id="h0002">1. Field of the Invention</heading>
<p id="p0001" num="0001">The present invention relates to a detection method for improving the PCR method and further for measuring multiple target nucleic acids, and art related to the same.</p>
<heading id="h0003">2. Description of the Related Art</heading>
<p id="p0002" num="0002">In genetic screening, it is necessary to measure multiple target nucleic acids in many cases.</p>
<p id="p0003" num="0003">For example, the multiple target nucleic acids may be: a first pair of influenza A viruses and influenza B viruses; a second pair of influenza and RSV/human metapneumovirus; a third pair of <i>Chlamydia trachomatis</i> and <i>Nisseria gonorrhoeae,</i> which may cause sexually transmitted diseases; a fourth pair of <i>Mycoplasma pneumoniae</i> and resistance factor thereof; and so on.</p>
<p id="p0004" num="0004">Regarding the multiple target nucleic acids in some pairs of the above, the conditions of patients are similar to each other and also infection of the same expands simultaneously. So, it is conceivable to distinguish the multiple target nucleic acids from each other to make a diagnosis, thereby deciding on a course of treatment.</p>
<p id="p0005" num="0005">Considering the resistance factor is effective for selecting/judging medication against thereto, or the like.</p>
<p id="p0006" num="0006">As for only one measurement item, it is also helpful to set up internal control<!-- EPO <DP n="2"> --> composition as means for confirming whether or not the measurement itself has been well done.</p>
<p id="p0007" num="0007">This is performed by: beforehand preparing a nucleic acid sequence to be amplified, the sequence not concerning a target gene of a detection object; and enabling to confirm whether or not the reaction has been well processed notwithstanding the existence or nonexistence of the target nucleic gene.</p>
<p id="p0008" num="0008">In this way, whether or not whether the reagent and the device for the measurement have acted effectively can be checked within the measurement system.</p>
<p id="p0009" num="0009">As mentioned above, in order to detect the multiple target nucleic acids, a first process of performing independent measurement for each of the multiple target nucleic acids, respectively, and a second process of distinguishing the multiple target nucleic acids from each other by means of different pilot dyes or the like, respectively can be conceived.</p>
<p id="p0010" num="0010">Alternatively, it is also possible to carry out the melting curve analysis method after having simultaneously processed amplification reaction. In this method after the amplification reaction, temperature is gradually increased/decreased to make distinction and judgment with respect to the multiple target nucleic acids based on both of first temperature wherein a change rate of fluorescent signals shows a peak and second temperature wherein the target nucleic acid is melt (the melting curve analysis method).</p>
<p id="p0011" num="0011">The first process of performing the independent measurement requires long time and high costs. The second process of distinguishing different labeling substances from each other costs too much because the second process needs not only preparing plural kinds of labeled reagents but also complicated wavelength-setting in an analyzer.</p>
<p id="p0012" num="0012"><!-- EPO <DP n="3"> --> A case by means of the melting curve analysis method costs less than the above. However, since the temperature must be gradually changed, it is necessary to take about 5 to 10 minutes for changing the temperature in order to conduct precise analysis.</p>
<p id="p0013" num="0013">Reference 1 (<patcit id="pcit0001" dnum="JP2002136300A"><text>Japanese application Laid-open No. 2002-136300</text></patcit>) discloses: preparing a plurality of reaction vessels containing different reaction solution from each other; and performing amplification and detection with the plurality of reaction vessels, respectively.</p>
<p id="p0014" num="0014">So, reagent preparation and dispensing operations must be conducted for every item of the plurality of reaction vessels. There is a problem that it requires a long time.</p>
<p id="p0015" num="0015">Reference 2 (<patcit id="pcit0002" dnum="JP2004000203A"><text>Japanese application Laid-open No. 2004-203</text></patcit>) discloses simultaneously amplifying multiple genes by means of one reaction vessel containing one kind of reaction solution.</p>
<p id="p0016" num="0016">Distinction is carried out by using different pilot dyes for each of the multiple genes. So, a plurality of optical systems installed in an analyzer are needed as many as the used pilot dyes. In other words, the analyzer costs too much. This is a serious problem.</p>
<p id="p0017" num="0017">Reference 3 (<patcit id="pcit0003" dnum="JP2008173127A"><text>Japanese application Laid-open No. 2008-173127</text></patcit>) discloses simultaneously amplifying multiple genes by means of one reaction vessel containing one kind of reaction solution.</p>
<p id="p0018" num="0018">Dissociation temperature of PCR products and labeled probes should be changed for every gene. After amplification, while temperature is gradually increased from a lower temperature side to a higher temperature side, dissociation curve analysis, which is a synonym of "melting curve analysis", of monitoring fluorescence values is carried out. Distinction is carried out by monitoring existence or nonexistence of a peak depending on base sequence at the respective dissociation temperature.<!-- EPO <DP n="4"> --></p>
<p id="p0019" num="0019">If temperature is changed speedily upon the melting curve analysis, it becomes difficult to identify melting temperature for each gene. Accordingly, there is a problem that extra time of about 5 to 10 minutes after PCR is required.</p>
<p id="p0020" num="0020">Reference 4 (<patcit id="pcit0004" dnum="JP2012513215W" dnum-type="L"><text>Japanese unexamined patent application publication &lt;Translation of PCT application&gt; No. 2012-513215</text></patcit>) discloses simultaneously amplifying multiple genes by means of one reaction vessel.</p>
<p id="p0021" num="0021">Dissociation temperature of PCR products and melting temperature of primers are changed for every gene. Distinction is carried out by monitoring fluorescence at the respective melting temperature.</p>
<p id="p0022" num="0022">In an ordinary PCR profile, one cycle includes: a denaturation step; and an annealing and elongation step. In Reference 4, the melting temperature of PCR products is changed for every gene. Accordingly, too many conditions should be taken into consideration, design of the profile is also difficult, and time for measurement must be too long.</p>
<p id="p0023" num="0023">Furthermore, there is another problem that temperature must be drastically changed to task the device.</p>
<p id="p0024" num="0024">Reference 6 (<patcit id="pcit0005" dnum="EP2787077A1" dnum-type="L"><text>European published patent application No. EP 2 787 077 A1</text></patcit>) discloses a method and a kit for detecting a target nucleic acid, wherein a fluorophore-labeled primer/probe and a quencher-labeled probe having complementarity to each other, have different melting temperatures (Tm) so that the fluorophore-labeled primer can anneal preferentially to the target nucleic acid, and the fluorophore-labeled primer that is not bound to the target nucleic acid is bound to a quenching probe so as to emit no fluorescence. In Reference 6, a plurality of detections must be performed for different labels at different wavelengths.<!-- EPO <DP n="5"> --></p>
<p id="p0025" num="0025">Reference 7 (<patcit id="pcit0006" dnum="EP2116614A1" dnum-type="L"><text>European published patent application No. EP 2 116 614 A1</text></patcit>) discloses a method for simultaneously amplifying and detecting nucleic acid sequences in a reaction comprising providing a sample comprising at least one nucleic acid molecule, providing reagents for performing an amplification reaction, wherein the reagents comprise at least three probe sets, wherein (a) each probe set consists of at least three probes, (b) each of the probes is specific for a nucleic acid sequence, (c) each of the probes in a given probe set carries a different label, (d) all of the probes in a given probe set have a similar, preferably identical melting temperature (T m ) when they are dissociated from their target nucleic acid sequence by heating, amplifying the nucleic acid sequences in the reaction, detecting the amplified nucleic acids by determining whether the labeled probe has bound its nucleic acid sequence, and detecting the temperature at which each given labeled probe dissociates from the nucleic acid sequence to which it has bound.</p>
<heading id="h0004">[List of cited References]</heading>
<p id="p0026" num="0026">
<ul id="ul0001" list-style="none" compact="compact">
<li>Reference 1: <patcit id="pcit0007" dnum="JP2002136300A"><text>Japanese application Laid-open No. 2002-136300</text></patcit>;</li>
<li>Reference 2: <patcit id="pcit0008" dnum="JP2004000203A"><text>Japanese application Laid-open No. 2004-203</text></patcit>;</li>
<li>Reference 3: <patcit id="pcit0009" dnum="JP2008173127A"><text>Japanese application Laid-open No. 2008-173127</text></patcit>;</li>
<li>Reference 4: <patcit id="pcit0010" dnum="JP2012513215W" dnum-type="L"><text>Japanese unexamined patent application publication (Translation of PCT application) No. 2012-513215</text></patcit>;</li>
<li>Reference 5: <patcit id="pcit0011" dnum="JP4724380B"><text>Japanese registered patent No. 4724380</text></patcit>;</li>
<li>Reference 6: <patcit id="pcit0012" dnum="EP2787077A1" dnum-type="L"><text>European published patent application No. EP 2 787 077 A1</text></patcit>; and</li>
<li>Reference 7: <patcit id="pcit0013" dnum="EP2116614A1" dnum-type="L"><text>European published patent application No. EP 2 116 614 A1</text></patcit>.</li>
</ul></p>
<heading id="h0005">OBJECTS AND SUMMARY OF THE INVENTION</heading>
<p id="p0027" num="0027">In view of the above, an object of the present invention is to provide a method for detecting multiple target nucleic acids capable of simultaneously amplifying and<!-- EPO <DP n="6"> --> detecting multiple genes by means of one reaction vessel containing one kind of reaction solution and one label.</p>
<p id="p0028" num="0028">A first aspect of the present invention provides a method for together detecting multiple target nucleic acids differing from each other, the multiple target nucleic acids including a first target nucleic acid and a second target nucleic acid, the method using a solution being capable of containing the first target nucleic acid and the second target nucleic acid therein, at a denaturation temperature TO, first double-stranded hydrogen bond of the first target nucleic acid being cut off to be dissociate into first two single strands, second double-stranded hydrogen bond of the second target nucleic acid being cut off to be dissociate into second two single strands, respectively, the solution further containing therein: a first target's primer at an annealing temperature T1 specifically bonding with either of the first two single strands into which the first target nucleic acid has been dissociated; a second target's primer at the annealing temperature T1 specifically bonding with either of the second two single strands into which the second target nucleic acid has been dissociated; a first target's probe at the annealing temperature T1 specifically bonding with either of the first two single strands into which the first target nucleic acid has been dissociated, the first target's probe including a first labeling substance changing first fluorescent signals thereof when the first target's probe specifically bonds with either of the first two single strands; DNA polymerase; deoxyribonucleoside triphoshate at an elongation temperature T2 bonding by action of the DNA polymerase with both of the first two single strands into which the first target nucleic acid has been dissociated and the second two single strands into which the second target nucleic acid has been dissociated; and a second target's probe at the annealing temperature T1 bonding with neither the first two single strands into which the first target nucleic acid has been dissociated nor the second two single strands into which the second target nucleic acid has been dissociated, the second target's probe at a<!-- EPO <DP n="7"> --> second target detection temperature T3 bonding with the second two single strands into which the second target nucleic acid has been dissociated, the second target's probe including a second labeling substance changing second fluorescent signals thereof when the second target's probe specifically bonds with either of the second two single strands, wherein T0 is defined as the denaturation temperature; T1 is defined as the annealing temperature; T2 is defined as the elongation temperature; T3 is defined as the second target detection temperature, T0 through T3 being set up such that a condition that: T0&gt;T2≥T1&gt;T3 is satisfied, and the first labeling substance and the second labeling substance are identical, wherein a difference caused by changes of the first and second fluorescent signals according to the second labeling substance is captured to judge existence or non existence of the second target nucleic acid.</p>
<p id="p0029" num="0029">The first labeling substance and the second labeling substance may be selected from a group consisting of: a QProbe (registered trademark) probe; an Eprobe (registered trademark) probe; and a TaqMan (registered trademark) probe.</p>
<p id="p0030" num="0030">The fluorescent signals may be shown by quenching light when the annealing occurs. Alternatively, the fluorescent signals may be shown by emitting light when the annealing occurs.</p>
<p id="p0031" num="0031">It is preferable that the first target nucleic acid is at least one of a <i>Mycoplasma pneumoniae</i> P1 gene and a <i>Chlamydia trachomatis</i> endogeneous plasmid gene, and the second target nucleic acid is at least one of internal control composition and a <i>Nisseria gonorrhoeae</i> CMT gene, respectively.</p>
<heading id="h0006">Effect of Invention</heading>
<p id="p0032" num="0032">As mentioned above, according to the present invention, the multiple target nucleic<!-- EPO <DP n="8"> --> acids can be detected by means of one kind of mixed-solution and one kind of labeling substances.</p>
<p id="p0033" num="0033">Distinction of the multiple target nucleic acids can be carried out without melting curve analysis. Accordingly, measuring time can be remarkably shortened, thereby providing excellent practical performance.</p>
<heading id="h0007">DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS</heading>
<p id="p0034" num="0034">The present inventors have developed a method for detecting nucleic acids by means of one kind of fluorescent labels and one reaction vessel containing one kind of reaction solution. Condition setting with respect to annealing temperature of probes and temperature change profiles in the PCR method has been incorporated within the present kit.</p>
<p id="p0035" num="0035">As shown in <figref idref="f0018">Fig. 35</figref>, the present kit uses four kinds of temperature including: denaturation temperature T0 (95 Centigrade); annealing temperature T1 (70 Centigrade); elongation temperature T2 (72 Centigrade); and second target detection temperature T3 (55 Centigrade).</p>
<p id="p0036" num="0036">The four kinds of temperature are set up such that a condition that T0 &gt; T2 &gt;= T1 &gt; T3 is satisfied.</p>
<p id="p0037" num="0037">Of course, the above temperature vales are mere examples, and may be variously changed as mentioned later.</p>
<p id="p0038" num="0038">Herein, the multiple target nucleic acids are a first target nucleic acid and a second target nucleic acid. However if needed, a third target nucleic acid or more can be added thereto by adding further setting such as third target detection temperature T4 (T3 &gt; T4), or the like.</p>
<p id="p0039" num="0039"><!-- EPO <DP n="9"> --> Referring now to <figref idref="f0019">Fig. 36</figref>, elements of the present kit will now be explained.</p>
<p id="p0040" num="0040">First, in the present kit, it is assumed that a first target nucleic acid 10 and a second target nucleic acid 20 are targets to be detected.</p>
<p id="p0041" num="0041">Hereinafter for the simplicity of explanation, only a case where both of the first target nucleic acid 10 and the second target nucleic acid 20 are contained in solution 2 within a vessel 1, that is, a case of positive and positive will be explained below. Details of the solution 2 will be mentioned later.</p>
<p id="p0042" num="0042">Needless to say, in another case where at least one target is negative, the solution 2 does not contain the at least one of the first target nucleic acid 10 and the second target nucleic acid 20. Therefore, fluorescent signals and amplification regarding the not contained target nucleic acid will not be carried out in the following explanation.</p>
<p id="p0043" num="0043">As shown in <figref idref="f0020">Fig. 37 (a)</figref>, when temperature of the solution 2 is increased to reach the denaturation temperature TO, hydrogen bonds of double strands of the first target nucleic acid 10 and the second target nucleic acid 20 are respectively cut off to be dissociated into respective first and second two single strands (from the first target nucleic acid 10 to a first single strand 11 and a second single strand 12, from second target nucleic acid 20 to a first single strand 21 and a second single strand 22).</p>
<p id="p0044" num="0044">As shown in <figref idref="f0020">Fig. 37 (b)</figref>, the temperature is decreased from the denaturation temperature T0 to reach the annealing temperature T1, regarding the first target nucleic acid 10, a first target's F-primer 13 specifically bonds with a complementary sequence of the first single strand 11, and a first target's R-primer 14 specifically bonds with another complementary sequence of the second single strand 12, respectively.</p>
<p id="p0045" num="0045">Furthermore, similar to the above, regarding the second target nucleic acid 20, a second target's F-primer 23 specifically bonds with a complementary sequence of the first<!-- EPO <DP n="10"> --> single strand 21, and a second target's R-primer 24 specifically bonds with another complementary sequence of the second single strand 22, respectively.</p>
<p id="p0046" num="0046">At the annealing temperature shown in <figref idref="f0020">Fig. 37 (b)</figref>, the first target's probe 15 labeled by means of the first labeling substance 16 specifically bonds with a specific part of the first single strand 11 derived from the first target nucleic acid 10, thereby the first labeling substance 16 outputs first fluorescence signals.</p>
<p id="p0047" num="0047">On the other hand, the annealing temperature is higher than the second target detection temperature T3. For this reason, the second target's probe 25 labeled by means of the second labeling substance 26 does not bond with the first single strand 21 derived from the second target nucleic acid 20, thereby the second labeling substance 26 outputs no fluorescence signal at this time.</p>
<p id="p0048" num="0048">As shown in <figref idref="f0021">Fig. 37 (c)</figref>, when the temperature is increased from the annealing temperature to the elongation temperature T2, amplification reaction progresses advances as follows. This is because the solution 2 contains an amount sufficient for repeating PCR cycles of DNA polymerase 30 and deoxyribonucleoside triphoshate 31.</p>
<p id="p0049" num="0049">Regarding the first target nucleic acid 10, from the first target's F-primer 13 bonding with the first single strand 11, and from the first target's R-primer 14 bonding with the second single strand 12, the deoxyribonucleoside triphoshate 31 bonds therewith to elongate, respectively.</p>
<p id="p0050" num="0050">Regarding the second target nucleic acid 20, from the second target's F-primer 23 bonding with the first single strand 21, and from the second target's R-primer 24 bonding with the second single strand 22, the deoxyribonucleoside triphoshate 31 bonds therewith to elongate, respectively.<!-- EPO <DP n="11"> --></p>
<p id="p0051" num="0051">As clear comparing <figref idref="f0021">Fig. 37 (d)</figref> with <figref idref="f0019">Fig. 36</figref>, upon the amplification reaction has been completed, both of the first target nucleic acid 10 and the second target nucleic acid 20 have been doubled.</p>
<p id="p0052" num="0052">Returning to a step shown in <figref idref="f0020">Fig. 37 (a)</figref> again to repeat the above steps of <figref idref="f0020">Fig. 37 (a)</figref> through <figref idref="f0021">Fig. 37 (d)</figref> enables to repeat the amplification reaction and changes of fluorescent signals by means of the first labeling substance 16.</p>
<p id="p0053" num="0053">Next referring now to <figref idref="f0022">Fig. 38</figref>, a case where the temperature is decreased from the denaturation temperature T0 to the second target detection temperature T3 will now be explained.</p>
<p id="p0054" num="0054">As shown in <figref idref="f0022">Fig. 38 (a)</figref>, at the denaturation temperature T0, the situation is the same as that of <figref idref="f0020">Fig. 37 (a)</figref>.</p>
<p id="p0055" num="0055">However, upon the temperature is decreased to reach the second target temperature detection temperature T3, the situation is as shown in <figref idref="f0022">Fig. 38 (b)</figref> differing from <figref idref="f0020">Fig. 37 (b)</figref>.</p>
<p id="p0056" num="0056">Namely, as shown in <figref idref="f0022">Fig. 38 (b)</figref>, the first target's probe 15 labeled by the first labeling substance 16 specifically bonds with a specific part of the first single strand 11 derived from the first target nucleic acid 10, and the first fluorescent signals of the first labeling substance 16 change. This is the same as that of <figref idref="f0020">Fig. 37 (b)</figref>.</p>
<p id="p0057" num="0057">However, the temperature is the second target detection temperature T3. Accordingly, also the second target's probe 25 labeled by the second labeling substance 26 bonds with the first single strand 21 derived from the second target nucleic acid 20, and the second fluorescent signals of the second labeling substance 26 also change.<!-- EPO <DP n="12"> --></p>
<p id="p0058" num="0058">Herein, the first labeling substance 16 and the second labeling substance 26 are identical.</p>
<p id="p0059" num="0059">As a result, capturing the difference caused by the changes of the first and second fluorescent signals according to the second labeling substance 26 enables to judge the existence or nonexistence (positivity/negativity) of the second target nucleic acid 20.</p>
<p id="p0060" num="0060">In addition as clear from the above-mentioned, it may be understood that the multiple target nucleic acids can be respectively detected during a series of continuing steps by means of the reaction vessel containing one kind of reaction solution.</p>
<p id="p0061" num="0061">Hereinafter, Embodiments of detecting multiple nucleic acids by means of three kinds of probes will now be explained more concretely. In the Embodiments, the QProbe (registered trademark) method, the Eprobe (registered trademark) method, and the TaqMan (registered trademark) method have been used.</p>
<p id="p0062" num="0062">Necessary information for operation including: primer sequences; base sequences of the respectivEprobes; and material of nucleic acid samples will be also shown.</p>
<heading id="h0008">(Embodiment 1)</heading>
<heading id="h0009">&lt;Detection of <i>Mycoplasma pneumoniae</i> P1 genes and internal control composition according to the QProbe method&gt;</heading>
<p id="p0063" num="0063">Detection of <i>Mycoplasma pneumoniae</i> P1 genes and internal control composition according to the QProbe method has been performed.</p>
<heading id="h0010">&lt;Material and steps&gt;</heading>
<heading id="h0011">(Primer)</heading><!-- EPO <DP n="13"> -->
<p id="p0064" num="0064">A pair of primers used for the PCR method in Embodiment 1 are as shown in Table 1.
<tables id="tabl0001" num="0001">
<table frame="bottom">
<title>(Table 1)</title>
<tgroup cols="3" colsep="0">
<colspec colnum="1" colname="col1" colwidth="24mm"/>
<colspec colnum="2" colname="col2" colwidth="76mm"/>
<colspec colnum="3" colname="col3" colwidth="21mm"/>
<thead>
<row>
<entry namest="col1" nameend="col3" align="left" valign="top">Primers used for PCR in this Embodiment</entry></row>
<row>
<entry valign="top">Primer name</entry>
<entry valign="top">Sequence(5'→3')</entry>
<entry align="center" valign="top">Length (bp)</entry></row></thead>
<tbody>
<row>
<entry>MYC F</entry>
<entry>GCCACCCTCGGGGGCAGTCAG (SEQ ID No. 1)</entry>
<entry align="center">21</entry></row>
<row>
<entry>MYC R</entry>
<entry>GAGTCGGGATTCCCCGCGGAGG (SEQ ID No. 2)</entry>
<entry align="center">22</entry></row></tbody></tgroup>
</table>
</tables></p>
<p id="p0065" num="0065">As sequence No. 1 and sequence No. 2, (primer pair for P1 adhesin gene) sequences recited in the report (<nplcit id="ncit0001" npl-type="s"><text>The Journal Of Infectious Diseases, 1996; 173; 1445 - 52) by Ieven </text></nplcit>et al. have been used.</p>
<heading id="h0012">(Nucleic acid sample)</heading>
<p id="p0066" num="0066">Nucleic acid samples used for the PCR method in Embodiment 1 are shown below.</p>
<heading id="h0013">(pMYC)</heading>
<p id="p0067" num="0067"><i>Mycoplasma pneumoniae</i> is a pathogenic organism of <i>Mycoplasma pneumonia.</i> P1 protein is membrane protein derived from <i>Mycoplasma pneumoniae.</i> Gene fragments (sequences amplified by a pair of primers of SEQ ID NO: 1 and SEQ ID NO: 2) encode the P1 protein. pMYC is a plasmid DNA produced by artificial synthesizing the gene fragments to be incorporated into a pMD20T vector. Production of the plasmid DNA has been performed by requesting custom synthesis to the Takara Bio Inc.</p>
<heading id="h0014">(pICM5)</heading>
<p id="p0068" num="0068">In order to be capable of amplifying pICM5 plasmid by means of common primers of the pair of primers of SEQ ID NO: 1 and SEQ ID NO: 2, pICM5 is a plasmid DNA produced by artificial synthesizing a sequence including a complementary sequence to the pair of the primers to be incorporated into a pMD20T vector. Production of the<!-- EPO <DP n="14"> --> plasmid DNA has been performed by requesting custom synthesis to the Takara Bio Inc.</p>
<heading id="h0015">(Preparation of nucleic acid sample)</heading>
<p id="p0069" num="0069">First length of the pMYC plasmid is 2942 [bp], and second length of the pICM5 plasmid is 2886 [bp].</p>
<p id="p0070" num="0070">Based on the first and second length and the concentration [µg/µl] of plasmid solution, the number of copies per 1 [µl] has been calculated. After that, by means of TE buffer solution (10 [mM] Tris-HCl, 1.0 [mM] EDTA pH: 8.0), the pMYC plasmid has been diluted to be 1×10<sup>5</sup> [copies/µl], and the pICM5 plasmid has been diluted to be 1×10<sup>3</sup> [copies/µl], respectively.</p>
<heading id="h0016">(probe)</heading>
<p id="p0071" num="0071">Information of thEprobe used for the PCR method in Embodiment 1 is as shown in Table 2.
<tables id="tabl0002" num="0002">
<table frame="bottom">
<title>(Table 2)</title>
<tgroup cols="3" colsep="0">
<colspec colnum="1" colname="col1" colwidth="23mm"/>
<colspec colnum="2" colname="col2" colwidth="83mm"/>
<colspec colnum="3" colname="col3" colwidth="21mm"/>
<thead>
<row>
<entry namest="col1" nameend="col3" align="left" valign="top">Probes used for PCR in this Embodiment</entry></row>
<row>
<entry valign="top">Probe name</entry>
<entry valign="top">Sequence(5'→3')</entry>
<entry align="center" valign="top">Length (bp)</entry></row></thead>
<tbody>
<row>
<entry>MYC QP</entry>
<entry>CCCTCGACCAAGCCAACCTCCAGCTC (SEQ ID No. 3)</entry>
<entry align="center">26</entry></row>
<row>
<entry>IC QP</entry>
<entry>AGTGGGACTCACCAACC (SEQ ID No. 4)</entry>
<entry align="center">17</entry></row></tbody></tgroup>
</table>
</tables></p>
<p id="p0072" num="0072">Based on a basic sequence of PCR products capable of being amplified by means of the pair of primers in Table 1, a specific region for SEQ ID NO: 3 and SEQ ID NO: 4 has been selected referring to Tm values calculated with a QProbe design support tool on the J-Bio21 Center home pages.</p>
<p id="p0073" num="0073">"MYC QP" is one QProbe specifically annealing the pMYC plasmid, and "IC QP" is<!-- EPO <DP n="15"> --> another QProbe specifically annealing the pICM5 plasmid. As fluorescent dye for both of "MYC QP" and "IC QP", "BODIPY FL" (registered trademark) has been used to label "C" at 3' ends, respectively. Production of the QProbes has been performed by requesting custom synthesis to the NIPPON STEEL &amp; SUMIKIN Eco-Tech Corporation.</p>
<heading id="h0017">(Conditions of PCR and fluorescence measurement)</heading>
<p id="p0074" num="0074">In Embodiment 1, among two kinds of target nucleic acids to be amplified within one vessel containing one kind of reaction liquid, a first Tm value for "MYC QP" that is the QProbe specifically annealing the pMYC plasmid of the first target is set up to be higher than another Tm value for the primers to perform first detection during amplification reaction.</p>
<p id="p0075" num="0075">In addition, a second Tm value for "IC QP" that is the QProbe specifically annealing the pICM5 plasmid of the second target is set up to be lower than changes (70 Centigrade to 95 Centigrade) of temperature during the amplification reaction to perform second detection after the amplification reaction.</p>
<p id="p0076" num="0076">Table 3 and Table 4 show composition of the PCR reaction solution and the reaction conditions respectively, and <figref idref="f0001">Fig. 1</figref> shows a graph of the changes of temperature of the mixed solution.<!-- EPO <DP n="16"> -->
<tables id="tabl0003" num="0003">
<table frame="bottom">
<title>(Table 3)</title>
<tgroup cols="2" colsep="0">
<colspec colnum="1" colname="col1" colwidth="46mm"/>
<colspec colnum="2" colname="col2" colwidth="36mm"/>
<thead>
<row>
<entry namest="col1" nameend="col2" align="left" valign="top">Composition of PCR solution in QProbe method</entry></row>
<row>
<entry align="center" valign="top">Solution composition</entry>
<entry align="center" valign="top">Final concentration</entry></row></thead>
<tbody>
<row rowsep="0">
<entry align="center">MilliQ(TM) water</entry>
<entry align="center">-</entry></row>
<row rowsep="0">
<entry align="center">PCR buffer</entry>
<entry align="center">× 1</entry></row>
<row rowsep="0">
<entry align="center">dNTP Mix</entry>
<entry align="center">150µM</entry></row>
<row rowsep="0">
<entry align="center">MYC F</entry>
<entry align="center">0.20µM</entry></row>
<row rowsep="0">
<entry align="center">MYC R</entry>
<entry align="center">0.60µM</entry></row>
<row rowsep="0">
<entry align="center">MYC QP</entry>
<entry align="center">0.15µM</entry></row>
<row rowsep="0">
<entry align="center">IC QP</entry>
<entry align="center">0.15µM</entry></row>
<row rowsep="0">
<entry align="center">KOD exo (-) DNA Polymerase</entry>
<entry align="center">0.0125U/µl</entry></row>
<row>
<entry align="center">Target nucleic acid</entry>
<entry align="center">-</entry></row></tbody></tgroup>
</table>
</tables>
The above has been prepared to be 20 µ L
<tables id="tabl0004" num="0004">
<table frame="bottom">
<title>(Table 4)</title>
<tgroup cols="4" colsep="0">
<colspec colnum="1" colname="col1" colwidth="43mm"/>
<colspec colnum="2" colname="col2" colwidth="15mm"/>
<colspec colnum="3" colname="col3" colwidth="15mm"/>
<colspec colnum="4" colname="col4" colwidth="35mm"/>
<thead>
<row>
<entry namest="col1" nameend="col4" align="left" valign="middle">Reaction conditions in QProbe method</entry></row>
<row>
<entry align="center" valign="middle">Reaction steps</entry>
<entry namest="col2" nameend="col3" align="left" valign="middle">Temperature(°C)</entry>
<entry valign="middle">Time(s)</entry></row></thead>
<tbody>
<row>
<entry align="center" valign="middle">Initial denaturation</entry>
<entry valign="middle">95</entry>
<entry valign="middle">T<sub>0</sub></entry>
<entry valign="middle">120</entry></row>
<row rowsep="0">
<entry morerows="2" rowsep="1" align="center" valign="middle">Amplification (1 - 44 cycles)</entry>
<entry valign="middle">95</entry>
<entry valign="middle">T<sub>0</sub></entry>
<entry valign="middle">10 (FL measurement)</entry></row>
<row rowsep="0">
<entry valign="middle">70</entry>
<entry valign="middle">T<sub>1</sub></entry>
<entry valign="middle">10</entry></row>
<row>
<entry valign="middle">72</entry>
<entry valign="middle">T<sub>2</sub></entry>
<entry valign="middle">10 (FL measurement)</entry></row>
<row rowsep="0">
<entry morerows="1" rowsep="1" align="center" valign="middle">Second target NA detecting</entry>
<entry valign="middle">95</entry>
<entry valign="middle">T<sub>0</sub></entry>
<entry valign="middle">10 (FL measurement)</entry></row>
<row>
<entry valign="middle">55</entry>
<entry valign="middle">T<sub>3</sub></entry>
<entry valign="middle">10 (FL measurement)</entry></row></tbody></tgroup>
</table>
</tables></p>
<p id="p0077" num="0077">For the PCR and the fluorescence measurement, "Light Cycler nano system" (registered trademark of the Roche Diagnostics K.K.) has been used.</p>
<p id="p0078" num="0078">The combination of 510 to 528 [nm] has been selected for excitation wavelength and fluorescent wavelength upon fluorescence measurement. Fluorescence values have been<!-- EPO <DP n="17"> --> measured at the denaturation step (95 Centigrade) and the elongation step (72 Centigrade) for every cycle. Furthermore, after the amplification reaction has been completed, at a step for detecting the second target (95 Centigrade and 55 Centigrade), fluorescence measurement has been performed.</p>
<p id="p0079" num="0079"><figref idref="f0001">Fig. 2</figref> shows fluorescent measurement conditions at the final cycle of the amplification reaction and at the second target detection step.</p>
<heading id="h0018">(How to process data)</heading>
<p id="p0080" num="0080">Analysis software provided with the Light Cycler nano system does not support an analysis method of using the QProbes. Accordingly, correction calculation has been performed on obtained raw data as follows, referring to a method disclosed in Reference 5 (<patcit id="pcit0014" dnum="JP4724380B"><text>Japanese registered patent No. 4724380</text></patcit>).</p>
<p id="p0081" num="0081">For every cycle of the amplification reaction and the second target detection step, calculation has been carried out according to the following formulae. <maths id="math0001" num="(Formula 1)"><math display="block"><mi>fn</mi><mo>=</mo><mi>fhyb</mi><mi>.n</mi><mo>/</mo><mi>fden</mi><mi>.n</mi></math><img id="ib0001" file="imgb0001.tif" wi="67" he="5" img-content="math" img-format="tif"/></maths> <maths id="math0002" num="(Formula 1')"><math display="block"><mi>fe</mi><mo>=</mo><mi>fhyb</mi><mi>.e</mi><mo>/</mo><mi>fden</mi><mi>.e</mi></math><img id="ib0002" file="imgb0002.tif" wi="68" he="5" img-content="math" img-format="tif"/></maths> herein,
<ul id="ul0002" list-style="none" compact="compact">
<li>fn: fluorescence intensity value in n cycle calculated according to Formula 1;</li>
<li>fhyb.n: fluorescence intensity value at the elongation step in n-th cycle;</li>
<li>fden.n: fluorescence intensity value at the denaturation step in n-th cycle;</li>
<li>fe: fluorescence intensity value at the second target detection step calculated according to Formula 1';</li>
<li>fhyb.e: fluorescence intensity value (55 Centigrade) at the second target detection step; and</li>
<li>fden.e: fluorescence intensity value (95 Centigrade) at the second target detection step.</li>
</ul><!-- EPO <DP n="18"> --></p>
<p id="p0082" num="0082">Next, for every cycle of the amplification reaction and the second target detection step, calculation has been carried out according to the following formulae. <maths id="math0003" num="(Formula 2)"><math display="block"><mi>Fn</mi><mo>=</mo><mi>fn</mi><mo>/</mo><mi mathvariant="normal">f</mi><mn>10</mn></math><img id="ib0003" file="imgb0003.tif" wi="52" he="5" img-content="math" img-format="tif"/></maths> <maths id="math0004" num="(Formula 2')"><math display="block"><mi>Fe</mi><mo>=</mo><mi>fe</mi><mo>/</mo><mi mathvariant="normal">f</mi><mn>10</mn></math><img id="ib0004" file="imgb0004.tif" wi="53" he="5" img-content="math" img-format="tif"/></maths> herein,
<ul id="ul0003" list-style="none" compact="compact">
<li>Fn: relative value in n-th cycle assuming that the fluorescence intensity value in the tenth cycle obtained according to Formula 1 is equal to a value of "1"; and</li>
<li>Fe: relative value at the second target detection step assuming that the fluorescence intensity value in the tenth cycle obtained according to Formula 1' is equal to a value of "1".</li>
</ul></p>
<p id="p0083" num="0083">F44 which is a value of Fn at the final cycle of the amplification reaction has been used for judgment of the existence or nonexistence of the first target nucleic acid.</p>
<p id="p0084" num="0084">Further calculation has been carried out according to the following formula. <maths id="math0005" num="(Formula 3)"><math display="block"><mi>Fs</mi><mo>=</mo><mi>Fe</mi><mo>−</mo><mi mathvariant="normal">F</mi><mn>44</mn></math><img id="ib0005" file="imgb0005.tif" wi="52" he="5" img-content="math" img-format="tif"/></maths> herein,<br/>
Fs: measured value regarding the second target.</p>
<p id="p0085" num="0085">The value of Fs has been used for determination of the existence or nonexistence of the second target nucleic acid.</p>
<p id="p0086" num="0086">Determination according to the QProbe method has been performed using the method shown below.</p>
<p id="p0087" num="0087">The F44 value of the measurement sample has been compared with Threshold 1. And, when the F44 value of the measurement sample is lower than Threshold 1, it has been determined that the first target nucleic acid is positive (existence), otherwise negative<!-- EPO <DP n="19"> --> (nonexistence).</p>
<p id="p0088" num="0088">As Threshold 1, an average of F44 values of the negative reference (reagent TE buffer added thereto instead of DNA) minus three times the standard deviation (hereinafter, called as "mean - 3SD") has been used.</p>
<p id="p0089" num="0089">Notwithstanding the first target nucleic acid is positive or negative, the Fs value has been compared with Threshold 2, and when the Fs value is lower than Threshold 2 it has been determined that the second target nucleic acid is positive (existence), otherwise negative (nonexistence).</p>
<p id="p0090" num="0090">As Threshold 2, the value of "mean - 3SD" of a sample to which only the pMYC plasmid is added has been used. <figref idref="f0002">Fig. 3</figref> shows a flow chart of the determination method related thereto.</p>
<p id="p0091" num="0091">As nucleic acid samples, the pMYC plasmid has been used for <i>Mycoplasma pneumoniae</i> P1 genes, the pICM5 plasmid has been used for the internal control composition, and the PCR has been performed thereon.</p>
<p id="p0092" num="0092">A first Tm value of 72.5 Centigrade has been set for a sequence of MYC QP, and a second Tm value of 57.5 Centigrade has been set for a sequence of IC QP. For this reason, it has been estimated that probes anneal only MYC QP during the temperature range (from 70 Centigrade to 95 Centigrade) in the PCR.</p>
<p id="p0093" num="0093">Since the fluorescence measurement with respect to the second target detection step has been carried out at 95 Centigrade and 55 Centigrade which is lower than the Tm value of IC QP, it has been estimated that extinction of both of MYC QP and the IC QP has<!-- EPO <DP n="20"> --> been simultaneously detected according to measured values at the second target detection step.</p>
<p id="p0094" num="0094">Regarding an amplification curve of the negative reference, extinction has not observed until 44 cycles when the PCR ends. This is because a value 0.998 of F44 is not lower than a value 0.997 of Threshold 1. At this time, "mean - 3SD" is equal to 0 .997 to be regarded as Threshold 1 for the first target detection in Embodiment 1, thereby being shown in Table 5. The amplification curve related thereto is also shown in <figref idref="f0002">Fig. 4</figref>.</p>
<p id="p0095" num="0095">Regarding another amplification curve of the pMYC plasmid of the first target nucleic acid, extinction caused by annealing of MYC QP has been observed from about 28 cycles.</p>
<p id="p0096" num="0096">It has been revealed that a value 0.913 of F44 has been lower than Threshold 1, and further that a first objective region of the pMYC plasmid has been amplified. At this time, "mean - 3SD" of Fs has been equal to -0.056 to be regarded as Threshold 2 for the second target detection, thereby being shown in Table 5. The amplification curve related thereto is also shown in <figref idref="f0003">Fig. 5</figref>.</p>
<p id="p0097" num="0097">Regarding an amplification curve of the pICM5 plasmid of the second target nucleic acid, no extinction has been observed during the amplification reaction. This is because a value 0.997 of F44 is not lower than a value 0.997 of Threshold 1. A value -0.118 of Fs has been lower than Threshold 2.</p>
<p id="p0098" num="0098">The above-mentioned results have revealed that the objective region of the pMYC plasmid has been not amplified, further that the objective region of the pICM5 plasmid has been amplified.<!-- EPO <DP n="21"> --></p>
<p id="p0099" num="0099">Table 5 shows the value of the Fs. The amplification curve is shown in <figref idref="f0003">Fig. 6</figref>.
<tables id="tabl0005" num="0005">
<table frame="bottom">
<title>(Table 5)</title>
<tgroup cols="5" colsep="0">
<colspec colnum="1" colname="col1" colwidth="33mm"/>
<colspec colnum="2" colname="col2" colwidth="19mm"/>
<colspec colnum="3" colname="col3" colwidth="20mm"/>
<colspec colnum="4" colname="col4" colwidth="15mm"/>
<colspec colnum="5" colname="col5" colwidth="24mm"/>
<thead>
<row>
<entry namest="col1" nameend="col5" align="left" valign="top">Values used for determination in QProbe method</entry></row>
<row>
<entry valign="top"/>
<entry align="center" valign="top">TE</entry>
<entry align="center" valign="top">pMYC</entry>
<entry align="center" valign="top">pICM5</entry>
<entry align="center" valign="top">pMYC pICM5</entry></row></thead>
<tbody>
<row>
<entry>F44</entry>
<entry align="center">0.998</entry>
<entry align="center">0.913</entry>
<entry align="center">0.997</entry>
<entry align="center">0.912</entry></row>
<row>
<entry>F44 (Average - 3SD)</entry>
<entry align="center">0.997 <img id="ib0006" file="imgb0006.tif" wi="4" he="4" img-content="character" img-format="tif" inline="yes"/>1</entry>
<entry align="center">-</entry>
<entry align="center">-</entry>
<entry align="center">-</entry></row>
<row>
<entry>Fe</entry>
<entry align="center">0.971</entry>
<entry align="center">0.862</entry>
<entry align="center">0.879</entry>
<entry align="center">0.796</entry></row>
<row>
<entry>Fs</entry>
<entry align="center">- 0.027</entry>
<entry align="center">-0.051</entry>
<entry align="center">-0.118</entry>
<entry align="center">-0.116</entry></row>
<row>
<entry>Fs (Average - 3SD)</entry>
<entry align="center">-</entry>
<entry align="center">-0.056 <img id="ib0007" file="imgb0006.tif" wi="4" he="4" img-content="character" img-format="tif" inline="yes"/>2</entry>
<entry align="center">-</entry>
<entry align="center">-</entry></row></tbody></tgroup>
<tgroup cols="5" rowsep="0">
<colspec colnum="1" colname="col1" colwidth="33mm"/>
<colspec colnum="2" colname="col2" colwidth="19mm"/>
<colspec colnum="3" colname="col3" colwidth="20mm"/>
<colspec colnum="4" colname="col4" colwidth="15mm"/>
<colspec colnum="5" colname="col5" colwidth="24mm"/>
<tbody>
<row>
<entry namest="col1" nameend="col5" align="justify"><img id="ib0008" file="imgb0006.tif" wi="4" he="4" img-content="character" img-format="tif" inline="yes"/> 1 Threshold 1 <img id="ib0009" file="imgb0006.tif" wi="4" he="4" img-content="character" img-format="tif" inline="yes"/>2 Threshold 2</entry></row></tbody></tgroup>
</table>
</tables></p>
<p id="p0100" num="0100">Regarding an amplification curve upon both the pMYC plasmid of the first target nucleic acid and the pICM5 plasmid of the second target nucleic acid have been added to the solution, extinction caused by annealing of MYC QP has been observed from about 28 cycles as the same as the above-mentioned amplification curve of the pMYC plasmid. A value 0.912 of F44 has been lower than Threshold 1, and it has been revealed that the objective region of the pMYC plasmid has been amplified.</p>
<p id="p0101" num="0101">The value -0.116 of Fs is lower than Threshold 2, and it has been revealed that the objective region of the pICM5 plasmid has been amplified. Table 5 shows the value of the Fs. The amplification curve related thereto is shown in <figref idref="f0004">Fig. 7</figref>.</p>
<p id="p0102" num="0102">After the PCR has been completed, agarose electrophoresis has been performed onto these PCR products. First objective PCR products with respect to the pMYC plasmid-added sample have been confirmed at near 206 [bp], and second objective PCR products with respect to the pICM5 plasmid-added sample have been confirmed at near 150 [bp].</p>
<p id="p0103" num="0103"><!-- EPO <DP n="22"> --> According to the above-mentioned results, it has been revealed that <i>Mycoplasma pneumoniae</i> P1 genes and internal control composition can be detected by means of one reaction vessel containing one kind of reaction solution and one kind of fluorescent labels when the method of designing probes and temperature profiles are incorporated with the QProbe method.</p>
<heading id="h0019">(Embodiment 2)</heading>
<heading id="h0020">&lt;Detection of <i>Mycoplasma pneumoniae</i> P1 genes and internal control composition based on QProbe method while changing profile at second detection step&gt;</heading>
<p id="p0104" num="0104">According to a method of changing the profiles at the second detection step in Embodiment 1, <i>Mycoplasma pneumoniae</i> P1 genes and internal control composition have been detected based on the QProbe method.</p>
<p id="p0105" num="0105">The primers, probes, reaction solution composition, and nucleic acids have been used for the PCR method as the same as Embodiment 1. Table 6 shows reaction conditions in Embodiment 2.
<tables id="tabl0006" num="0006">
<table frame="bottom">
<title>(Table 6)</title>
<tgroup cols="4" colsep="0">
<colspec colnum="1" colname="col1" colwidth="43mm"/>
<colspec colnum="2" colname="col2" colwidth="23mm"/>
<colspec colnum="3" colname="col3" colwidth="23mm"/>
<colspec colnum="4" colname="col4" colwidth="35mm"/>
<thead>
<row>
<entry namest="col1" nameend="col4" align="left" valign="middle">Reaction conditions after profile at second NA target detecting step is changed</entry></row>
<row>
<entry align="center" valign="middle">Reaction steps</entry>
<entry namest="col2" nameend="col3" align="left" valign="middle">Temperature(°C)</entry>
<entry valign="middle">Time(s)</entry></row></thead>
<tbody>
<row>
<entry align="center" valign="middle">Initial denaturation</entry>
<entry valign="middle">95</entry>
<entry valign="middle">T<sub>0</sub></entry>
<entry valign="middle">120</entry></row>
<row rowsep="0">
<entry morerows="2" rowsep="1" align="center" valign="middle">Amplification (1 - 44 cycles)</entry>
<entry valign="middle">95</entry>
<entry valign="middle">T<sub>0</sub></entry>
<entry valign="middle">10 (FL measurement)</entry></row>
<row rowsep="0">
<entry valign="middle">70</entry>
<entry valign="middle">T<sub>1</sub></entry>
<entry valign="middle">10</entry></row>
<row>
<entry valign="middle">72</entry>
<entry valign="middle">T<sub>2</sub></entry>
<entry valign="middle">10 (FL measurement)</entry></row>
<row>
<entry align="center" valign="middle">Second target NA detecting</entry>
<entry valign="middle">55</entry>
<entry valign="middle">T<sub>3</sub></entry>
<entry valign="middle">10 (FL measurement)</entry></row></tbody></tgroup>
</table>
</tables></p>
<p id="p0106" num="0106"><!-- EPO <DP n="23"> --> At the second target detection step in Embodiment 2, fluorescence measurement has been conducted at 55 Centigrade. <figref idref="f0004">Fig. 8</figref> shows fluorescent measurement conditions at the final cycle of the amplification reaction and at the second target detection step.</p>
<p id="p0107" num="0107">In Embodiment 2, fe has been calculated as follows. Calculation other than fe has been carried out as the same as Embodiment 1. <maths id="math0006" num=""><math display="block"><mi>fe</mi><mo>=</mo><mi>fhybe</mi><mo>.</mo><mi mathvariant="normal">e</mi><mo>/</mo><mi>fden</mi><mn>.44</mn></math><img id="ib0010" file="imgb0010.tif" wi="36" he="5" img-content="math" img-format="tif"/></maths> herein,
<ul id="ul0004" list-style="none" compact="compact">
<li>fe: fluorescence intensity value at the second target detection step;</li>
<li>fhyb.e: fluorescence intensity value (55 Centigrade) at the second target detection step;</li>
<li>fden. 44: fluorescence intensity value (95 Centigrade) at the final cycle of amplification reaction.</li>
</ul></p>
<p id="p0108" num="0108">Determination in Embodiment 2 has been performed as below.</p>
<p id="p0109" num="0109">The F44 value of the measurement sample has been compared with Threshold 3. And, when the F44 value of the measurement sample is lower than Threshold 3, it has been determined that the first target nucleic acid is positive (existence), otherwise negative (nonexistence).</p>
<p id="p0110" num="0110">As Threshold 3, an average of F44 values of the negative reference minus three times the standard deviation (hereinafter, called as "mean - 3SD") has been used.</p>
<p id="p0111" num="0111">Notwithstanding the first target nucleic acid is positive or negative, the Fs value has been compared with Threshold 4, and when the Fs value is lower than Threshold 4 it has been determined that the second target nucleic acid is positive (existence), otherwise negative (nonexistence).</p>
<p id="p0112" num="0112"><!-- EPO <DP n="24"> --> As Threshold 4, the value of "mean - 3SD" of a sample to which only the pMYC plasmid is added has been used.</p>
<p id="p0113" num="0113">Regarding an amplification curve of the negative reference, extinction has not observed until 44 cycles when the PCR ends. This is because a value 0.998 of F44 is not lower than a value 0.997 of Threshold 3. At this time, "mean - 3SD" is equal to 0 .997 to be regarded as Threshold 3 for the first target detection in this Embodiment, thereby being shown in Table 7. The amplification curve related thereto is also shown in <figref idref="f0005">Fig. 9</figref>.</p>
<p id="p0114" num="0114">Regarding another amplification curve of the pMYC plasmid of the first target nucleic acid, extinction caused by annealing of MYC QP has been observed from about 28 cycles. It has been revealed that a value 0.912 of F44 has been lower than Threshold 3, and further that the objective region of the pMYC plasmid has been amplified.</p>
<p id="p0115" num="0115">At this time, "mean - 3SD" of Fs has been equal to -0.052 to be regarded as Threshold 4 for the second target detection, thereby being shown in Table 7. The amplification curve related thereto is also shown in <figref idref="f0005">Fig. 10</figref>.</p>
<p id="p0116" num="0116">Regarding an amplification curve of the pICM5 plasmid, no extinction has been observed during the amplification reaction. This is because a value 0.997 of F44 is not lower than a value 0.997 of Threshold 3. A value -0.170 of Fs has been lower than Threshold 4.</p>
<p id="p0117" num="0117">The above-mentioned results have revealed that the objective region of the pMYC plasmid has been not amplified, further that the objective region of the pICM5 plasmid has been amplified. Table 7 shows the value of Fs. The amplification curve is shown in <figref idref="f0006">Fig. 11</figref>.<!-- EPO <DP n="25"> -->
<tables id="tabl0007" num="0007">
<table frame="bottom">
<title>(Table 7)</title>
<tgroup cols="5" colsep="0">
<colspec colnum="1" colname="col1" colwidth="34mm"/>
<colspec colnum="2" colname="col2" colwidth="29mm"/>
<colspec colnum="3" colname="col3" colwidth="30mm"/>
<colspec colnum="4" colname="col4" colwidth="30mm"/>
<colspec colnum="5" colname="col5" colwidth="30mm"/>
<thead>
<row>
<entry namest="col1" nameend="col5" align="left" valign="top">Values used for determination in QProbe method after profile at second NA target detecting step is changed</entry></row>
<row>
<entry valign="top"/>
<entry align="center" valign="top">TE</entry>
<entry align="center" valign="top">pMYC</entry>
<entry align="center" valign="top">pICM5</entry>
<entry align="center" valign="top">pMYC pICM5</entry></row></thead>
<tbody>
<row>
<entry>F44</entry>
<entry align="center">0.998</entry>
<entry align="center">0.912</entry>
<entry align="center">0.997</entry>
<entry align="center">0.911</entry></row>
<row>
<entry>F44 (Average - 3SD)</entry>
<entry align="center">0. 997 <img id="ib0011" file="imgb0006.tif" wi="4" he="4" img-content="character" img-format="tif" inline="yes"/>1</entry>
<entry align="center">-</entry>
<entry align="center">-</entry>
<entry align="center">-</entry></row>
<row>
<entry>Fe</entry>
<entry align="center">0.961</entry>
<entry align="center">0.869</entry>
<entry align="center">0.827</entry>
<entry align="center">0.797</entry></row>
<row>
<entry>Fs</entry>
<entry align="center">-0.037</entry>
<entry align="center">-0.043</entry>
<entry align="center">-0.170</entry>
<entry align="center">-0.114</entry></row>
<row>
<entry>Fs (Average - 3SD)</entry>
<entry align="center">-</entry>
<entry align="center">-0.052 <img id="ib0012" file="imgb0006.tif" wi="4" he="4" img-content="character" img-format="tif" inline="yes"/>2</entry>
<entry align="center">-</entry>
<entry align="center">-</entry></row></tbody></tgroup>
<tgroup cols="5" rowsep="0">
<colspec colnum="1" colname="col1" colwidth="34mm"/>
<colspec colnum="2" colname="col2" colwidth="29mm"/>
<colspec colnum="3" colname="col3" colwidth="30mm"/>
<colspec colnum="4" colname="col4" colwidth="30mm"/>
<colspec colnum="5" colname="col5" colwidth="30mm"/>
<tbody>
<row>
<entry namest="col1" nameend="col5" align="justify"><img id="ib0013" file="imgb0006.tif" wi="4" he="4" img-content="character" img-format="tif" inline="yes"/> 1 Threshold 3 <img id="ib0014" file="imgb0006.tif" wi="4" he="4" img-content="character" img-format="tif" inline="yes"/>2 Threshold 4</entry></row></tbody></tgroup>
</table>
</tables></p>
<p id="p0118" num="0118">Regarding an amplification curve upon both the pMYC plasmid of the first target nucleic acid and the pICM5 plasmid of the second target nucleic acid have been added to the solution as the above-mentioned amplification curve of the pMYC plasmid, extinction caused by annealing of MYC QP has been observed from about 28 cycles. A value 0.911 of F 44 has been lower than Threshold 3, and it has been revealed that the objective region of the pMYC plasmid has been amplified.</p>
<p id="p0119" num="0119">The value -0.114 of Fs is lower than Threshold 4, and it has been revealed that the objective region of the pICM5 plasmid has been amplified. Table 7 shows the value of the Fs. The amplification curve related thereto is shown in <figref idref="f0006">Fig. 12</figref>.</p>
<p id="p0120" num="0120">According to the above results, it has been revealed that upon using the fluorescence intensity value (95 Centigrade) at the final cycle of the amplification reaction (fden.44) the second target can be detected.</p>
<heading id="h0021">(Embodiment 3)</heading>
<heading id="h0022">&lt;Detection of <i>Mycoplasma pneumoniae</i> P1 genes and internal control composition based on Eprobe method&gt;</heading>
<p id="p0121" num="0121"><!-- EPO <DP n="26"> --> <i>Mycoplasma pneumoniae</i> P1 genes and internal control composition have been detected based on the Eprobe method.</p>
<p id="p0122" num="0122">The same primers and nucleic acid samples for PCR as Embodiment 1 have been used. Table 8 shows probe information used for the PCR in Embodiment 3.
<tables id="tabl0008" num="0008">
<table frame="topbot">
<title>(Table 8)</title>
<tgroup cols="3" colsep="0">
<colspec colnum="1" colname="col1" colwidth="23mm"/>
<colspec colnum="2" colname="col2" colwidth="83mm"/>
<colspec colnum="3" colname="col3" colwidth="21mm"/>
<thead>
<row>
<entry namest="col1" nameend="col3" align="left" valign="top">Probes used for PCR in this Embodiment</entry></row>
<row>
<entry valign="top">Probe name</entry>
<entry valign="top">Sequence(5'→3')</entry>
<entry align="center" valign="top">Length (bp)</entry></row></thead>
<tbody>
<row>
<entry>MYC EP</entry>
<entry>CCCTCGACCAAGCCAACCTCCAGCTC(SEQ ID No. 3)</entry>
<entry align="center">26</entry></row>
<row>
<entry>IC EP</entry>
<entry>AGTGGGACTCACCAAC (SEQ ID No.5)</entry>
<entry align="center">16</entry></row></tbody></tgroup>
</table>
</tables></p>
<p id="p0123" num="0123">A specific region for Eprobe has been selected referring to Tm values calculated by means of "Edesign" software produced by the K. K. Dnaform.</p>
<p id="p0124" num="0124">"MYC EP" is one Eprobe specifically annealing the pMYC plasmid, and "IC EP" is another Eprobe specifically annealing the pICM5 plasmid. As fluorescent dye for both of "MYC EP" and "IC EP", "D514" has been used. The nineteenth "T" from 5' end of "MYC EP" and the ninth "T" from 5' end of "IC EP" have been labeled, respectively.</p>
<p id="p0125" num="0125">Production of the Eprobes has been performed by requesting custom synthesis to the Eurofins Genomics K.K. The PCR reaction solution composition and the reaction conditions are shown in Table 9 and Table 10.<!-- EPO <DP n="27"> -->
<tables id="tabl0009" num="0009">
<table frame="bottom">
<title>(Table 9)</title>
<tgroup cols="2" colsep="0">
<colspec colnum="1" colname="col1" colwidth="45mm"/>
<colspec colnum="2" colname="col2" colwidth="36mm"/>
<thead>
<row>
<entry namest="col1" nameend="col2" align="left" valign="top">Composition of PCR solution in EProbe method</entry></row>
<row>
<entry align="center" valign="top">Solution composition</entry>
<entry align="center" valign="top">Final concentration</entry></row></thead>
<tbody>
<row rowsep="0">
<entry align="center">MilliQ(TM) water</entry>
<entry align="center">-</entry></row>
<row rowsep="0">
<entry align="center">PCR buffer</entry>
<entry align="center">× 1</entry></row>
<row rowsep="0">
<entry align="center">dNTP Mix</entry>
<entry align="center">150µM</entry></row>
<row rowsep="0">
<entry align="center">MYC F</entry>
<entry align="center">0.20µM</entry></row>
<row rowsep="0">
<entry align="center">MYC R</entry>
<entry align="center">0.80µM</entry></row>
<row rowsep="0">
<entry align="center">MYC EP</entry>
<entry align="center">0.40µM</entry></row>
<row rowsep="0">
<entry align="center">IC EP</entry>
<entry align="center">0.40µM</entry></row>
<row rowsep="0">
<entry align="center">KOD exo (-) DNA Polymerase</entry>
<entry align="center">0.0125U/µl</entry></row>
<row>
<entry align="center">Target nucleic acid</entry>
<entry align="center">-</entry></row></tbody></tgroup>
</table>
</tables>
The above has been prepared to be 20 µ L
<tables id="tabl0010" num="0010">
<table frame="bottom">
<title>(Table 10)</title>
<tgroup cols="4" colsep="0">
<colspec colnum="1" colname="col1" colwidth="43mm"/>
<colspec colnum="2" colname="col2" colwidth="15mm"/>
<colspec colnum="3" colname="col3" colwidth="15mm"/>
<colspec colnum="4" colname="col4" colwidth="35mm"/>
<thead>
<row>
<entry namest="col1" nameend="col4" align="left" valign="middle">Reaction conditions in EProbe method</entry></row>
<row>
<entry align="center" valign="middle">Reaction steps</entry>
<entry namest="col2" nameend="col3" align="left" valign="middle">Temperature(°C)</entry>
<entry valign="middle">Time(s)</entry></row></thead>
<tbody>
<row>
<entry align="center" valign="middle">Initial denaturation</entry>
<entry valign="middle">95</entry>
<entry valign="middle">T<sub>0</sub></entry>
<entry valign="middle">120</entry></row>
<row rowsep="0">
<entry morerows="2" rowsep="1" align="center" valign="middle">Amplification (1 - 40 cycles)</entry>
<entry valign="middle">95</entry>
<entry valign="middle">T<sub>0</sub></entry>
<entry valign="middle">10 (FL measurement)</entry></row>
<row rowsep="0">
<entry valign="middle">70</entry>
<entry valign="middle">T<sub>1</sub></entry>
<entry valign="middle">10</entry></row>
<row>
<entry valign="middle">72</entry>
<entry valign="middle">T<sub>2</sub></entry>
<entry valign="middle">10 (FL measurement)</entry></row>
<row rowsep="0">
<entry morerows="1" rowsep="1" align="center" valign="middle">Second target NA detecting</entry>
<entry valign="middle">95</entry>
<entry valign="middle">T<sub>0</sub></entry>
<entry valign="middle">10 (FL measurement)</entry></row>
<row>
<entry valign="middle">55</entry>
<entry valign="middle">T<sub>3</sub></entry>
<entry valign="middle">10 (FL measurement)</entry></row></tbody></tgroup>
</table>
</tables></p>
<p id="p0126" num="0126">The combination of 530 to 548 [nm] has been selected for excitation wavelength and fluorescent wavelength upon fluorescence measurement.</p>
<p id="p0127" num="0127">Fs in Embodiment 3 has been calculated with the following Formula. The other calculations have been carried out as the same as Embodiment 1.<!-- EPO <DP n="28"> --> <maths id="math0007" num=""><math display="block"><mi>Fs</mi><mo>=</mo><mi>Fe</mi><mo>−</mo><mi mathvariant="normal">F</mi><mn>40</mn></math><img id="ib0015" file="imgb0015.tif" wi="25" he="4" img-content="math" img-format="tif"/></maths></p>
<p id="p0128" num="0128">Determination in Embodiment 3 has been performed using the method shown below. The F40 value of the measurement sample has been compared with Threshold 5. And, when the F40 value of the measurement sample is higher than Threshold 5, it has been determined that the first target nucleic acid is positive (existence), otherwise negative (nonexistence).</p>
<p id="p0129" num="0129">As Threshold 5, an average of F40 values of the negative reference plus three times the standard deviation (hereinafter, called as "mean + 3SD") has been used.</p>
<p id="p0130" num="0130">Notwithstanding the first target nucleic acid is positive or negative, the Fs value has been compared with Threshold 6, and when the Fs value is higher than Threshold 6, it has been determined that the second target nucleic acid is positive (existence), otherwise negative (nonexistence).</p>
<p id="p0131" num="0131">As Threshold 6, the value of "mean + 3SD" of a sample to which only the pMYC plasmid is added has been used. <figref idref="f0007">Fig. 13</figref> shows a flow chart of the determination method related thereto.</p>
<p id="p0132" num="0132">A first Tm value of 76.4 Centigrade has been set for a sequence of MYC EP, and a second Tm value of 59.8 Centigrade has been set for a sequence of IC EP. For this reason, it has been estimated that probes anneal only MYC EP during the temperature range (from 70 Centigrade to 95 Centigrade) in the PCR.</p>
<p id="p0133" num="0133">Since the fluorescence measurement with respect to the second target detection step has been carried out at 95 Centigrade and 55 Centigrade which is lower than the Tm value<!-- EPO <DP n="29"> --> of IC EP, it has been estimated that emission of both of MYC EP and the IC EP has been simultaneously detected according to measured values at the second target detection step.</p>
<p id="p0134" num="0134">Regarding an amplification curve of the negative reference, emission has not observed until 40 cycles when the PCR ends. This is because a value 1.007 of F40 is not higher than a value 1.013 of Threshold 5. At this time, "mean + 3SD" is equal to 1.013 to be regarded as Threshold 5 for the first target detection, thereby being shown in Table 11. The amplification curve related thereto is also shown in <figref idref="f0007">Fig. 14</figref>.</p>
<p id="p0135" num="0135">Regarding another amplification curve of the pMYC plasmid of the first target nucleic acid, emission caused by annealing of MYC EP has been observed from about 29 cycles. It has been revealed that a value 2.314 of F40 has been higher than Threshold 5, and further that the objective region of the pMYC plasmid has been amplified.</p>
<p id="p0136" num="0136">At this time, "mean + 3SD" of Fs has been equal to 3.695 to be regarded as Threshold 6 for the second target detection, thereby being shown in Table 11. The amplification curve related thereto is also shown in <figref idref="f0008">Fig. 15</figref>.</p>
<p id="p0137" num="0137">Regarding an amplification curve of the pICM5 plasmid of the second target nucleic acid, no emission has been observed during the amplification reaction. This is because a value 1.012 of F40 is not higher than a value 1.013 of Threshold 5. A value 4.012 of Fs has been higher than Threshold 6.</p>
<p id="p0138" num="0138">The above-mentioned results have revealed that the objective region of the pMYC plasmid has been not amplified, further that the objective region of the pICM5 plasmid has been amplified. The value of Fs is shown in Table 11, and the amplification curve<!-- EPO <DP n="30"> --> related thereto is also shown in <figref idref="f0008">Fig. 16</figref>.
<tables id="tabl0011" num="0011">
<table frame="topbot">
<title>(Table 11)</title>
<tgroup cols="5" colsep="0">
<colspec colnum="1" colname="col1" colwidth="33mm"/>
<colspec colnum="2" colname="col2" colwidth="19mm"/>
<colspec colnum="3" colname="col3" colwidth="20mm"/>
<colspec colnum="4" colname="col4" colwidth="15mm"/>
<colspec colnum="5" colname="col5" colwidth="24mm"/>
<thead>
<row>
<entry namest="col1" nameend="col5" align="left" valign="top">Values used for determination in EProbe method</entry></row>
<row>
<entry valign="top"/>
<entry align="center" valign="top">TE</entry>
<entry align="center" valign="top">pMYC</entry>
<entry align="center" valign="top">pICM5</entry>
<entry align="center" valign="top">pMYC pICM5</entry></row></thead>
<tbody>
<row>
<entry>F40</entry>
<entry align="center">1.007</entry>
<entry align="center">2.314</entry>
<entry align="center">1.012</entry>
<entry align="center">2.355</entry></row>
<row>
<entry>F40 (Average+3SD)</entry>
<entry align="center">1.013 <img id="ib0016" file="imgb0006.tif" wi="4" he="4" img-content="character" img-format="tif" inline="yes"/>1</entry>
<entry align="center">-</entry>
<entry align="center">-</entry>
<entry align="center">-</entry></row>
<row>
<entry>Fe</entry>
<entry align="center">3.149</entry>
<entry align="center">5.837</entry>
<entry align="center">5.024</entry>
<entry align="center">6.609</entry></row>
<row>
<entry>Fs</entry>
<entry align="center">2.142</entry>
<entry align="center">3.523</entry>
<entry align="center">4.012</entry>
<entry align="center">4.254</entry></row>
<row>
<entry>Fs (Average+3SD)</entry>
<entry align="center">-</entry>
<entry align="center">3.695 <img id="ib0017" file="imgb0006.tif" wi="4" he="4" img-content="character" img-format="tif" inline="yes"/>2</entry>
<entry align="center">-</entry>
<entry align="center">-</entry></row></tbody></tgroup>
<tgroup cols="5" rowsep="0">
<colspec colnum="1" colname="col1" colwidth="33mm"/>
<colspec colnum="2" colname="col2" colwidth="19mm"/>
<colspec colnum="3" colname="col3" colwidth="20mm"/>
<colspec colnum="4" colname="col4" colwidth="15mm"/>
<colspec colnum="5" colname="col5" colwidth="24mm"/>
<tbody>
<row>
<entry namest="col1" nameend="col5" align="justify"><img id="ib0018" file="imgb0006.tif" wi="4" he="4" img-content="character" img-format="tif" inline="yes"/> 1 Threshold 5 <img id="ib0019" file="imgb0006.tif" wi="4" he="4" img-content="character" img-format="tif" inline="yes"/>2 Threshold 6</entry></row></tbody></tgroup>
</table>
</tables></p>
<p id="p0139" num="0139">Regarding an amplification curve upon both the pMYC plasmid of the first target nucleic acid and the pICM5 plasmid of the second target nucleic acid have been added to the solution, emission caused by annealing of MYC EP has been observed from about 29 cycles as the same as the above-mentioned amplification curve of the pMYC plasmid. A value 2.355 of F40 has been higher than Threshold 5, and it has been revealed that the objective region of the pMYC plasmid has been amplified.</p>
<p id="p0140" num="0140">A value 4.254 of Fs is higher than Threshold 6, and it has been revealed that the objective region of the pICM5 plasmid has been amplified. Table 11 shows the value of the Fs. The amplification curve related thereto is shown in <figref idref="f0009">Fig. 17</figref>.</p>
<p id="p0141" num="0141">According to the above-mentioned results, it has been revealed that <i>Mycoplasma pneumoniae</i> P1 genes and internal control composition can be detected by means of one reaction vessel containing one kind of reaction solution and one kind of fluorescent labels when the method of designing probes and temperature profiles are combined even with the Eprobe method.</p>
<heading id="h0023">(Embodiment 4)</heading><!-- EPO <DP n="31"> -->
<p id="p0142" num="0142">&lt;Detection of <i>Mycoplasma pneumoniae</i> P1 genes and internal control composition based on TaqMan probe method&gt;</p>
<p id="p0143" num="0143">According to the TaqMan probe method, <i>Mycoplasma pneumoniae</i> P1 genes and internal control composition have been detected. The primers and nucleic acid samples have been used for the PCR method as the same of Embodiment 1.</p>
<p id="p0144" num="0144">Table 12 shows information of the probes used for the PCR method in Embodiment 4.
<tables id="tabl0012" num="0012">
<table frame="topbot">
<title>(Table 12)</title>
<tgroup cols="3" colsep="0">
<colspec colnum="1" colname="col1" colwidth="22mm"/>
<colspec colnum="2" colname="col2" colwidth="81mm"/>
<colspec colnum="3" colname="col3" colwidth="21mm" colsep="1"/>
<thead>
<row>
<entry namest="col1" nameend="col2" align="left" valign="top">Probes used for PCR in this Embodiment</entry>
<entry valign="top"/></row>
<row>
<entry valign="top">Probe name</entry>
<entry valign="top">Sequence(5'→3')</entry>
<entry valign="top">Length (bp)</entry></row></thead>
<tbody>
<row>
<entry>MYC Taq</entry>
<entry>CCCTCGACCAAGCCAACCTCCAGCTC SEQ ID No. 3</entry>
<entry>26</entry></row>
<row>
<entry>IC Taq</entry>
<entry>AGTGGGACTCACCAACC SEQ ID No. 4</entry>
<entry>17</entry></row></tbody></tgroup>
</table>
</tables></p>
<p id="p0145" num="0145">A specific region for the TaqMan probe has been selected referring to Tm values calculated according to the nearest neighbor method.</p>
<p id="p0146" num="0146">"MYC Taq" is one TaqMan probe specifically annealing the pMYC plasmid, and "IC Taq" is another TaqMan probe specifically annealing the pICM5 plasmid. As fluorescent dye for both of "MYC Taq" and "IC Taq", "FAM" (registered trademark) has been used to be labeled at 5' end and "TAMRA" (registered trademark) has been used to be labeled at 3' end, respectively.</p>
<p id="p0147" num="0147">Production of the TaqMan probes has been performed by requesting custom synthesis to the Takara Bio Inc. Table 13 and Table 14 show composition of PCR solution and reaction conditions related thereto, respectively.<!-- EPO <DP n="32"> -->
<tables id="tabl0013" num="0013">
<table frame="all">
<title>(Table 13)</title>
<tgroup cols="2" colsep="0">
<colspec colnum="1" colname="col1" colwidth="41mm"/>
<colspec colnum="2" colname="col2" colwidth="41mm" colsep="1"/>
<thead>
<row>
<entry namest="col1" nameend="col2" align="left" valign="top">Composition of PCR solution in TaqMan Probe method</entry></row>
<row>
<entry align="center" valign="top">Solution composition</entry>
<entry align="center" valign="top">Solution composition</entry></row></thead>
<tbody>
<row rowsep="0">
<entry align="center">MilliQ(TM) water</entry>
<entry align="center">-</entry></row>
<row rowsep="0">
<entry align="center">PCR buffer</entry>
<entry align="center">×1</entry></row>
<row rowsep="0">
<entry align="center">dNTP Mix</entry>
<entry align="center">150µM</entry></row>
<row rowsep="0">
<entry align="center">MYC F</entry>
<entry align="center">0.50µM</entry></row>
<row rowsep="0">
<entry align="center">MYC R</entry>
<entry align="center">0.50µM</entry></row>
<row rowsep="0">
<entry align="center">MYC Taq</entry>
<entry align="center">0.30µM</entry></row>
<row rowsep="0">
<entry align="center">IC Taq</entry>
<entry align="center">0.30µM</entry></row>
<row rowsep="0">
<entry align="center">TaKaRa Ex Taq (TM)</entry>
<entry align="center">0.025 U/µl</entry></row>
<row>
<entry align="center">Target nucleic acid</entry>
<entry align="center">-</entry></row></tbody></tgroup>
</table>
</tables>
The above has been prepared to be 20 µ L
<tables id="tabl0014" num="0014">
<table frame="all">
<title>(Table 14)</title>
<tgroup cols="4" colsep="0">
<colspec colnum="1" colname="col1" colwidth="43mm"/>
<colspec colnum="2" colname="col2" colwidth="15mm"/>
<colspec colnum="3" colname="col3" colwidth="15mm"/>
<colspec colnum="4" colname="col4" colwidth="35mm" colsep="1"/>
<thead>
<row>
<entry namest="col1" nameend="col4" align="left" valign="top">Reaction conditions in TaqMan probe method</entry></row>
<row>
<entry align="center" valign="top">Reaction steps</entry>
<entry namest="col2" nameend="col3" align="left" valign="top">Temperature(°C)</entry>
<entry valign="top">Time(s)</entry></row></thead>
<tbody>
<row>
<entry align="center">Initial denaturation</entry>
<entry>95</entry>
<entry>T<sub>0</sub></entry>
<entry>120</entry></row>
<row rowsep="0">
<entry morerows="2" rowsep="1" align="center">Amplification (1 - 44 cycles)</entry>
<entry>95</entry>
<entry>T<sub>0</sub></entry>
<entry>5 (FL measurement)</entry></row>
<row rowsep="0">
<entry>70</entry>
<entry>T<sub>1</sub></entry>
<entry>15</entry></row>
<row>
<entry>72</entry>
<entry>T<sub>2</sub></entry>
<entry>0 (FL measurement)</entry></row>
<row rowsep="0">
<entry morerows="1" rowsep="1" align="center">Second target NA detecting</entry>
<entry>95</entry>
<entry>T<sub>0</sub></entry>
<entry>5 (FL measurement)</entry></row>
<row>
<entry>50</entry>
<entry>T<sub>3</sub></entry>
<entry>15 (FL measurement)</entry></row></tbody></tgroup>
</table>
</tables></p>
<p id="p0148" num="0148">The combination of 530 to 548 [nm] has been selected for excitation wavelength and fluorescent wavelength upon fluorescence measurement.</p>
<p id="p0149" num="0149">At a step for detecting the second target (95 Centigrade and 50 Centigrade) after<!-- EPO <DP n="33"> --> amplification reaction, fluorescence measurement has been performed.</p>
<p id="p0150" num="0150">In Embodiment 4, fhyb.e has been defined as a fluorescence intensity value (50 Centigrade), and the same calculation except this point as Embodiment 1 has been conducted.</p>
<p id="p0151" num="0151">Determination in Embodiment 4 has been performed as below.</p>
<p id="p0152" num="0152">The F44 value of the measurement sample has been compared with Threshold 7. And, when the F44 value of the measurement sample is higher than Threshold 7, it has been determined that the first target nucleic acid is positive (existence), otherwise negative (nonexistence).</p>
<p id="p0153" num="0153">As Threshold 7, an average of F44 values of the negative reference plus three times the standard deviation (hereinafter, called as "mean + 3SD") has been used.</p>
<p id="p0154" num="0154">Notwithstanding the first target nucleic acid is positive or negative, the Fs value has been compared with Threshold 8, and when the Fs value is higher than Threshold 8, it has been determined that the second target nucleic acid is positive (existence), otherwise negative (nonexistence).</p>
<p id="p0155" num="0155">As Threshold 8, the value of "mean + 3SD" of a sample to which only the pMYC plasmid is added has been used.</p>
<p id="p0156" num="0156">A first Tm value of 75.8 Centigrade has been set for a sequence of MYC Taq, and a second Tm value of 53.7 Centigrade has been set for a sequence of IC Taq. For this reason, it has been estimated that probes anneal only MYC Taq during the temperature range (from 70 Centigrade to 95 Centigrade) in the PCR.<!-- EPO <DP n="34"> --></p>
<p id="p0157" num="0157">Since the fluorescence measurement with respect to the second target detection step has been carried out at 95 Centigrade and 50 Centigrade which is lower than the Tm value of IC Taq, it has been estimated that emission of both of MYC Taq and the IC Taq has been simultaneously detected according to measured values at the second target detection step.</p>
<p id="p0158" num="0158">Regarding an amplification curve of the negative reference, emission has not observed until 44 cycles when the PCR ends. This is because a value 1.028 of F44 is not higher than a value 1.028 of Threshold 7. At this time, "mean + 3SD" is equal to 1.028 to be regarded as Threshold 7 for the first target detection, thereby being shown in Table 15. The amplification curve related thereto is also shown in <figref idref="f0009">Fig. 18</figref>.</p>
<p id="p0159" num="0159">Regarding another amplification curve of the pMYC plasmid of the first target nucleic acid, emission caused by annealing of MYC Taq has been observed from about 28 cycles. It has been revealed that a value 1.427 of F44 has been higher than Threshold 7, and further that the objective region of the pMYC plasmid has been amplified.</p>
<p id="p0160" num="0160">At this time, "mean + 3SD" of Fs has been equal to 0.110 to be regarded as Threshold 8 for the second target detection, thereby being shown in Table 15. The amplification curve related thereto is also shown in <figref idref="f0010">Fig. 19</figref>.<!-- EPO <DP n="35"> -->
<tables id="tabl0015" num="0015">
<table frame="topbot">
<title>(Table 15)</title>
<tgroup cols="5" colsep="0">
<colspec colnum="1" colname="col1" colwidth="34mm"/>
<colspec colnum="2" colname="col2" colwidth="20mm"/>
<colspec colnum="3" colname="col3" colwidth="19mm"/>
<colspec colnum="4" colname="col4" colwidth="16mm"/>
<colspec colnum="5" colname="col5" colwidth="25mm" colsep="1"/>
<thead>
<row>
<entry namest="col1" nameend="col5" align="left" valign="top">Values used for determination in TaqMan Probe method</entry></row>
<row>
<entry valign="top"/>
<entry align="center" valign="top">TE</entry>
<entry align="center" valign="top">pMYC</entry>
<entry align="center" valign="top">pICM5</entry>
<entry align="center" valign="top">pMYC pICM5</entry></row></thead>
<tbody>
<row>
<entry>F44</entry>
<entry align="center">1.028</entry>
<entry align="center">1.427</entry>
<entry align="center">1.028</entry>
<entry align="center">1.348</entry></row>
<row>
<entry>F44 (Average + 3SD)</entry>
<entry align="center">1.028 <img id="ib0020" file="imgb0006.tif" wi="4" he="4" img-content="character" img-format="tif" inline="yes"/>1</entry>
<entry align="center">-</entry>
<entry align="center">-</entry>
<entry align="center">-</entry></row>
<row>
<entry>Fe</entry>
<entry align="center">1.060</entry>
<entry align="center">1.536</entry>
<entry align="center">1.158</entry>
<entry align="center">1.525</entry></row>
<row>
<entry>Fs</entry>
<entry align="center">0.032</entry>
<entry align="center">0.109</entry>
<entry align="center">0.130</entry>
<entry align="center">0.177</entry></row>
<row>
<entry>Fs (Average + 3SD)</entry>
<entry align="center">-</entry>
<entry align="center">0.110 <img id="ib0021" file="imgb0006.tif" wi="4" he="4" img-content="character" img-format="tif" inline="yes"/>2</entry>
<entry align="center">-</entry>
<entry align="center">-</entry></row></tbody></tgroup>
<tgroup cols="5" rowsep="0">
<colspec colnum="1" colname="col1" colwidth="34mm"/>
<colspec colnum="2" colname="col2" colwidth="20mm"/>
<colspec colnum="3" colname="col3" colwidth="19mm"/>
<colspec colnum="4" colname="col4" colwidth="16mm"/>
<colspec colnum="5" colname="col5" colwidth="25mm"/>
<tbody>
<row>
<entry namest="col1" nameend="col5" align="justify"><img id="ib0022" file="imgb0006.tif" wi="4" he="4" img-content="character" img-format="tif" inline="yes"/> 1 Threshold 7 <img id="ib0023" file="imgb0006.tif" wi="4" he="4" img-content="character" img-format="tif" inline="yes"/>2 Threshold 8</entry></row></tbody></tgroup>
</table>
</tables></p>
<p id="p0161" num="0161">Regarding an amplification curve of the pICM5 plasmid of the second target nucleic acid, no emission has been observed during the amplification reaction. This is because a value 1.028 of F44 is not higher than a value 1.028 of Threshold 7. A value 0.130 of Fs has been higher than Threshold 8.</p>
<p id="p0162" num="0162">The above-mentioned results have revealed that the objective region of the pMYC plasmid has been not amplified, further that the objective region of the pICM5 plasmid has been amplified.</p>
<p id="p0163" num="0163">Table 15 shows the value of the Fs. The amplification curve is shown in <figref idref="f0010">Fig. 20</figref>.</p>
<p id="p0164" num="0164">Regarding an amplification curve upon both the pMYC plasmid of the first target nucleic acid and the pICM5 plasmid of the second target nucleic acid have been added to the solution, emission caused by annealing of MYC EP has been observed from about 29 cycles as the same as the above-mentioned amplification curve of the pMYC plasmid. A value 1.348 of F40 has been higher than Threshold 7, and it has been revealed that the objective region of the pMYC plasmid has been amplified.</p>
<p id="p0165" num="0165">A value 0.177 of Fs is higher than Threshold 8, and it has been revealed that the<!-- EPO <DP n="36"> --> objective region of the pICM5 plasmid has been amplified. Table 15 shows the value of the Fs. The amplification curve related thereto is shown in <figref idref="f0011">Fig. 21</figref>.</p>
<p id="p0166" num="0166">According to the above-mentioned results, it has been revealed that <i>Mycoplasma pneumoniae</i> P1 genes and internal control composition can be detected by means of one reaction vessel containing one kind of reaction solution and one kind of fluorescent labels when the method of designing probes and temperature profiles are incorporated with even the TaqMan probe method.</p>
<heading id="h0024">(Embodiment 5)</heading>
<heading id="h0025">&lt;Detection of <i>Mycoplasma pneumoniae</i> P1 genes and internal control composition based on QProbe method with actual specimen&gt;</heading>
<p id="p0167" num="0167">According to the QProbe method, <i>Mycoplasma pneumoniae</i> P1 genes and internal control composition have been detected by means of actual specimens.</p>
<p id="p0168" num="0168">As <i>Mycoplasma pneumoniae</i> P1 genes, first total DNA has been used, the first total DNA having been extracted from first pharynx wiping liquid of which <i>Mycoplasma pneumoniae</i> has been determined to be positive (tested by the BML, Inc.) according to the LAMP method (<patcit id="pcit0015" dnum="JP3313358B"><text>Japanese registered patent No. 3313358</text></patcit>) by means of a "QIAamp" DNA mini Kit (registered trademark of the QIAGEN).</p>
<p id="p0169" num="0169">As negative samples, second total DNA has been used, the second total DNA having been extracted from second pharynx wiping liquid of which <i>Mycoplasma pneumoniae</i> has been determined to be negative according to the LAMP method by means of the "QIAamp" DNA mini Kit. PCR has been carried out under the same conditions other than this point as those of Embodiment 1.<!-- EPO <DP n="37"> --></p>
<p id="p0170" num="0170">The same calculation as Embodiment 1 has been performed on obtained raw data related thereto.</p>
<p id="p0171" num="0171">Determination in Embodiment 5 has been performed as below.</p>
<p id="p0172" num="0172">The F44 value of the measurement sample has been compared with Threshold 9. And, when the F44 value of the measurement sample is lower than Threshold 9, it has been determined that the first target nucleic acid is positive (existence), otherwise negative (nonexistence).</p>
<p id="p0173" num="0173">As Threshold 9, an average of F44 values of the negative reference minus three times the standard deviation (hereinafter, called as "mean - 3SD") has been used.</p>
<p id="p0174" num="0174">Notwithstanding the first target nucleic acid is positive or negative, the Fs value has been compared with Threshold 10, and when the Fs value is lower than Threshold 10, it has been determined that the second target nucleic acid is positive (existence), otherwise negative (nonexistence). As Threshold 10, the value of "mean - 3SD" with respect to Fs of the positive sample has been used.</p>
<p id="p0175" num="0175">Regarding an amplification curve of the negative reference, extinction has not observed until 44 cycles when the PCR ends. This is because a value 0.997 of F44 is not lower than a value 0.997 of Threshold 9. At this time, "mean - 3SD" is equal to 0 .997 to be regarded as Threshold 9 for the first target detection in this Embodiment, thereby being shown in Table 16. The amplification curve related thereto is also shown in <figref idref="f0011">Fig. 22</figref>.</p>
<p id="p0176" num="0176">Regarding another amplification curve of the positive reference of the first target nucleic acid, extinction caused by annealing of MYC QP has been observed from about<!-- EPO <DP n="38"> --> 35 cycles. It has been revealed that a value 0.951 of F44 has been lower than Threshold 9, and further that the objective region of the pMYC plasmid has been amplified.</p>
<p id="p0177" num="0177">At this time, "mean - 3SD" of Fs has been equal to -0.132 to be regarded as Threshold 10 for the second target detection, thereby being shown in Table 16. The amplification curve related thereto is also shown in <figref idref="f0012">Fig. 23</figref>.</p>
<p id="p0178" num="0178">Regarding an amplification curve of the pICM5 plasmid of the second target nucleic acid, no extinction has been observed during the amplification reaction. This is because a value 0.998 of F44 is not lower than a value 0.997 of Threshold 9. A value -0.227 of Fs has been lower than Threshold 10.</p>
<p id="p0179" num="0179">The above-mentioned results have revealed that the objective region of the pMYC plasmid has been not amplified, further that the objective region of the pICM5 plasmid has been amplified. A value of Fs is shown in Table 16, and the amplification curve related thereto is also shown in <figref idref="f0012">Fig. 24</figref>.</p>
<p id="p0180" num="0180">Regarding an amplification curve upon the positive reference of the first target nucleic acid has been added to the pICM5 plasmid of the second target nucleic acid, extinction caused by annealing of MYC QP has been observed from about 35 cycles as the same as the amplification curve of the positive reference. A value 0.953 of F44 has been lower than Threshold 9, and it has been revealed that the objective region of the pMYC plasmid has been amplified.</p>
<p id="p0181" num="0181">A value -0.235 of Fs is lower than Threshold 10, and it has been revealed that the objective region of the pICM5 plasmid has been amplified. Table 16 shows the value of the Fs. The amplification curve related thereto is shown in <figref idref="f0013">Fig. 25</figref>.<!-- EPO <DP n="39"> -->
<tables id="tabl0016" num="0016">
<table frame="topbot">
<title>(Table 16)</title>
<tgroup cols="5" colsep="0">
<colspec colnum="1" colname="col1" colwidth="33mm"/>
<colspec colnum="2" colname="col2" colwidth="28mm"/>
<colspec colnum="3" colname="col3" colwidth="27mm"/>
<colspec colnum="4" colname="col4" colwidth="19mm"/>
<colspec colnum="5" colname="col5" colwidth="36mm" colsep="1"/>
<thead>
<row>
<entry namest="col1" nameend="col5" align="left" valign="top">Values used for determination in QProbe method with actual specimen</entry></row>
<row>
<entry valign="top"/>
<entry align="center" valign="top">negative sample</entry>
<entry align="center" valign="top">positive sample</entry>
<entry align="center" valign="top">pICM5</entry>
<entry align="center" valign="top">positive sample pICM5</entry></row></thead>
<tbody>
<row>
<entry>F44</entry>
<entry align="center">0.997</entry>
<entry align="center">0.951</entry>
<entry align="center">0.998</entry>
<entry align="center">0.953</entry></row>
<row>
<entry>F44 (Average - 3SD)</entry>
<entry align="center">0.997 <img id="ib0024" file="imgb0006.tif" wi="4" he="4" img-content="character" img-format="tif" inline="yes"/>1</entry>
<entry align="center">-</entry>
<entry align="center">-</entry>
<entry align="center">-</entry></row>
<row>
<entry>Fe</entry>
<entry align="center">0.920</entry>
<entry align="center">0.824</entry>
<entry align="center">0.771</entry>
<entry align="center">0.718</entry></row>
<row>
<entry>Fs</entry>
<entry align="center">- 0.077</entry>
<entry align="center">- 0.127</entry>
<entry align="center">- 0.227</entry>
<entry align="center">- 0.235</entry></row>
<row>
<entry>Fs (Average - 3SD)</entry>
<entry align="center">-</entry>
<entry align="center">- 0.132 <img id="ib0025" file="imgb0006.tif" wi="4" he="4" img-content="character" img-format="tif" inline="yes"/>2</entry>
<entry align="center">-</entry>
<entry align="center">-</entry></row></tbody></tgroup>
<tgroup cols="5" rowsep="0">
<colspec colnum="1" colname="col1" colwidth="33mm"/>
<colspec colnum="2" colname="col2" colwidth="28mm"/>
<colspec colnum="3" colname="col3" colwidth="27mm"/>
<colspec colnum="4" colname="col4" colwidth="19mm"/>
<colspec colnum="5" colname="col5" colwidth="36mm"/>
<tbody>
<row>
<entry namest="col1" nameend="col5" align="justify"><img id="ib0026" file="imgb0006.tif" wi="4" he="4" img-content="character" img-format="tif" inline="yes"/> 1 Threshold 9 <img id="ib0027" file="imgb0006.tif" wi="4" he="4" img-content="character" img-format="tif" inline="yes"/>2 Threshold 10</entry></row></tbody></tgroup>
</table>
</tables></p>
<p id="p0182" num="0182">According to the above-mentioned results, it has been revealed that <i>Mycoplasma pneumoniae</i> P1 genes and internal control composition can be detected by means of one reaction vessel containing one kind of reaction solution and one kind of fluorescent labels when the method of designing probes and temperature profiles are incorporated with the actual clinical specimens.</p>
<p id="p0183" num="0183">The present invention is also applicable for identifying subtypes and/or single nucleotide polymorphism of pathogenic organisms causing infectious diseases.</p>
<heading id="h0026">(Embodiment 6)</heading>
<heading id="h0027">&lt;Detection of <i>Chlamydia trachomatis</i> endogeneous plasmid gene and <i>Neisseria gonorrhoeae</i> CMT gene based on QProbe method&gt;</heading>
<p id="p0184" num="0184">According to the QProbe method, detection of <i>Chlamydia trachomatis</i> endogeneous plasmid genes and <i>Neisseria gonorrhoeae</i> CMT genes has been carried out.</p>
<heading id="h0028">(pCT)</heading>
<p id="p0185" num="0185">Production of pCT plasmids has been performed by requesting custom synthesis to the Hokkaido System Science Co., Ltd. Gene fragments of common endogenous plasmids<!-- EPO <DP n="40"> --> (pLGV440) of <i>Chlamydia trachomatis</i> which are pathogenic organisms causing Chlamydia infection have been artificially synthesized into plasmid DNA to be incorporated into a pUC57 vector, thereby having prepared the pCT plasmids.</p>
<heading id="h0029">(pNG)</heading>
<p id="p0186" num="0186">Production of pNG plasmids has also been performed by requesting custom synthesis to the Hokkaido System Science Co., Ltd. Gene fragments of cytosine DNA methyl transferase (CMT) of <i>Neisseria gonorrhoeae</i> which is a pathogenic organism causing gonorrhea have been artificially synthesized into plasmid DNA to be incorporated into a pUC57 vector, thereby having prepared the pNG plasmids.</p>
<p id="p0187" num="0187">First length of the pCT plasmid is 3064 [bp], and second length of the pNG plasmid is 3059 [bp].</p>
<p id="p0188" num="0188">Based on the first and second length and the concentration (µg/µl) of plasmid solution, the number of copies per 1 [µl] has been calculated. After that, by means of TE buffer solution (10 [mM] Tris-HCl, 1.0 [mM] EDTA pH: 8.0), both of the pCT plasmids and the pNG plasmids have been diluted to be 1×10<sup>5</sup> [copies/µl].</p>
<p id="p0189" num="0189">Primer pairs used in the PCR method in Embodiment 6 are as shown in Table 17.
<tables id="tabl0017" num="0017">
<table frame="all">
<title>(Table 17)</title>
<tgroup cols="3" colsep="0">
<colspec colnum="1" colname="col1" colwidth="24mm"/>
<colspec colnum="2" colname="col2" colwidth="105mm"/>
<colspec colnum="3" colname="col3" colwidth="21mm" colsep="1"/>
<thead>
<row>
<entry namest="col1" nameend="col3" align="left" valign="top">Primers used for PCR in this Embodiment</entry></row>
<row>
<entry valign="top">Primer name</entry>
<entry valign="top">Sequence(5'→3')</entry>
<entry valign="top">Length (bp)</entry></row></thead>
<tbody>
<row>
<entry>CT F</entry>
<entry>TGAGCACCCTAGGCGTTTGTACTCCGTCAC (SEQ ID No.6)</entry>
<entry align="center">30</entry></row>
<row>
<entry>CT R</entry>
<entry>GCACTTTCTACAAGAGTACATCGGTCAACGAAGAGG (SEQ ID No. 7)</entry>
<entry align="center">36</entry></row>
<row>
<entry>N G F</entry>
<entry>GGGCGTGGTTGAACTGGCAAAAAGC (SEQ ID No.8)</entry>
<entry align="center">25</entry></row>
<row>
<entry>N G R</entry>
<entry>CAGTGATTTTGGCATTGGCGATATTGG (SEQ ID No. 9)</entry>
<entry align="center">27</entry></row></tbody></tgroup>
</table>
</tables></p>
<p id="p0190" num="0190"><!-- EPO <DP n="41"> --> Information of thEprobes used in the PCR method in Embodiment 6 is as shown in Table 18.
<tables id="tabl0018" num="0018">
<table frame="all">
<title>(Table 18)</title>
<tgroup cols="3" colsep="0">
<colspec colnum="1" colname="col1" colwidth="23mm"/>
<colspec colnum="2" colname="col2" colwidth="85mm"/>
<colspec colnum="3" colname="col3" colwidth="21mm" colsep="1"/>
<thead>
<row>
<entry namest="col1" nameend="col3" align="left" valign="top">Probes used for PCR in this Embodiment</entry></row>
<row>
<entry valign="top">Probe name</entry>
<entry valign="top">Sequence(5'→3')</entry>
<entry align="center" valign="top">Length (bp)</entry></row></thead>
<tbody>
<row>
<entry>CT QP</entry>
<entry>TGCGGGCGATTTGCCTTAACCCCACC (SEQ ID No. 10)</entry>
<entry align="center">26</entry></row>
<row>
<entry>NG QP</entry>
<entry>CTAAGCAAAATTCGAGGGGGAAAAC (SEQ ID No. 11)</entry>
<entry align="center">25</entry></row></tbody></tgroup>
</table>
</tables></p>
<p id="p0191" num="0191">Based on a basic sequence of PCR products capable of being amplified by means of the pair of primers of SEQ ID NO: 6 and SEQ ID NO: 7, a specific region for CT QP has been selected referring to Tm values calculated with a QProbe design support tool on the J-Bio21 Center home pages.</p>
<p id="p0192" num="0192">Based on a basic sequence of PCR products capable of being amplified by means of the pair of primers of SEQ ID NO: 8 and SEQ ID NO: 9, a specific region for NG QP has been selected referring to Tm values calculated with the QProbe design support tool on the J-Bio21 Center home pages.</p>
<p id="p0193" num="0193">"CT QP" is one QProbe specifically annealing the pCT plasmid, and "NG QP" is another QProbe specifically annealing the pNG plasmid. As fluorescent dye for both of "CT QP" and "NG QP", "BODIPY FL" (registered trademark) has been used to label "C" at 3' ends, respectively.</p>
<p id="p0194" num="0194">Production of the QProbes has been performed by requesting custom synthesis to the NIPPON STEEL &amp; SUMIKIN Eco-Tech Corporation. Table 19 and Table 20 show composition of PCR solution and reaction conditions related thereto, respectively.<!-- EPO <DP n="42"> -->
<tables id="tabl0019" num="0019">
<table frame="bottom">
<title>(Table 19)</title>
<tgroup cols="2" colsep="0">
<colspec colnum="1" colname="col1" colwidth="46mm"/>
<colspec colnum="2" colname="col2" colwidth="34mm"/>
<thead>
<row>
<entry namest="col1" nameend="col2" align="left" valign="top">Composition of PCR solution</entry></row>
<row>
<entry align="center" valign="top">Solution composition</entry>
<entry align="center" valign="top">Final concentration</entry></row></thead>
<tbody>
<row rowsep="0">
<entry align="center">MilliQ(TM) water</entry>
<entry align="center">―</entry></row>
<row rowsep="0">
<entry align="center">PCR buffer</entry>
<entry align="center">× 1</entry></row>
<row rowsep="0">
<entry align="center">dNTP Mix</entry>
<entry align="center">150µM</entry></row>
<row rowsep="0">
<entry align="center">CT F</entry>
<entry align="center">0.20µM</entry></row>
<row rowsep="0">
<entry align="center">CT R</entry>
<entry align="center">0.60µM</entry></row>
<row rowsep="0">
<entry align="center">CT QP</entry>
<entry align="center">0.15µM</entry></row>
<row rowsep="0">
<entry align="center">NG F</entry>
<entry align="center">0.20µM</entry></row>
<row rowsep="0">
<entry align="center">NG R</entry>
<entry align="center">0.60µM</entry></row>
<row rowsep="0">
<entry align="center">NG QP</entry>
<entry align="center">0.15µM</entry></row>
<row rowsep="0">
<entry align="center">KOD exo (-) DNA Polymerase</entry>
<entry align="center">0.0125U/µl</entry></row>
<row>
<entry align="center">Target nucleic acid</entry>
<entry align="center">―</entry></row></tbody></tgroup>
</table>
</tables>
The above has been prepared to be 20 µ L
<tables id="tabl0020" num="0020">
<table frame="bottom">
<title>(Table 20)</title>
<tgroup cols="4" colsep="0">
<colspec colnum="1" colname="col1" colwidth="43mm"/>
<colspec colnum="2" colname="col2" colwidth="15mm"/>
<colspec colnum="3" colname="col3" colwidth="15mm"/>
<colspec colnum="4" colname="col4" colwidth="35mm"/>
<thead>
<row>
<entry namest="col1" nameend="col4" align="left" valign="middle">Reaction conditions of CT NG in QProbe method</entry></row>
<row>
<entry align="center" valign="middle">Reaction steps</entry>
<entry namest="col2" nameend="col3" align="left" valign="middle">Temperature(°C)</entry>
<entry valign="middle">Time(s)</entry></row></thead>
<tbody>
<row>
<entry align="center" valign="middle">Initial denaturation</entry>
<entry valign="middle">95</entry>
<entry valign="middle">T<sub>0</sub></entry>
<entry valign="middle">120</entry></row>
<row rowsep="0">
<entry morerows="1" rowsep="1" align="center" valign="middle">Amplification (1 - 44 cycles)</entry>
<entry valign="middle">95</entry>
<entry valign="middle">T<sub>0</sub></entry>
<entry valign="middle">5 (FL measurement)</entry></row>
<row>
<entry valign="middle">68</entry>
<entry valign="middle">T<sub>1</sub>,T<sub>2</sub></entry>
<entry valign="middle">15 (FL measurement)</entry></row>
<row rowsep="0">
<entry morerows="1" rowsep="1" align="center" valign="middle">Second target NA detecting</entry>
<entry valign="middle">95</entry>
<entry valign="middle">T<sub>0</sub></entry>
<entry valign="middle">5 (FL measurement)</entry></row>
<row>
<entry valign="middle">55</entry>
<entry valign="middle">T<sub>3</sub></entry>
<entry valign="middle">15 (FL measurement)</entry></row></tbody></tgroup>
</table>
</tables></p>
<p id="p0195" num="0195">The combination of 510 to 528 [nm] has been selected for excitation wavelength and fluorescent wavelength upon fluorescence measurement.</p>
<p id="p0196" num="0196">Fluorescence values have been measured at the denaturation step (95 Centigrade) and<!-- EPO <DP n="43"> --> the elongation step (68 Centigrade) for every cycle. Furthermore, after the amplification reaction has been completed, at a step for detecting the second target (95 Centigrade and 55 Centigrade), fluorescence measurement has been performed.</p>
<p id="p0197" num="0197">The same calculation as that of Embodiment 1 has been performed on obtained raw data related thereto.</p>
<p id="p0198" num="0198">Determination according to the QProbe method has been performed using the method shown below.</p>
<p id="p0199" num="0199">The F44 value of the measurement sample has been compared with Threshold 11. And, when the F44 value of the measurement sample is lower than Threshold 11, it has been determined that the first target nucleic acid is positive (existence), otherwise negative (nonexistence).</p>
<p id="p0200" num="0200">As Threshold 11, an average of F44 values of the negative reference minus three times the standard deviation (hereinafter, called as "mean - 3SD") has been used.</p>
<p id="p0201" num="0201">Notwithstanding the first target nucleic acid is positive or negative, the Fs value has been compared with Threshold 12, and when the Fs value is lower than Threshold 12, it has been determined that the second target nucleic acid is positive (existence), otherwise negative (nonexistence).</p>
<p id="p0202" num="0202">As Threshold 12, the value of "mean - 3SD" of a sample to which only the pNG plasmid is added has been used.</p>
<p id="p0203" num="0203">A first Tm value of 73.4 Centigrade has been set for a sequence of CT QP, and a second Tm value of 62.5 Centigrade has been set for a sequence of NG QP. For this reason, it<!-- EPO <DP n="44"> --> has been estimated that probes anneal only CT QP during the temperature range (from 68 Centigrade to 95 Centigrade) in the PCR.</p>
<p id="p0204" num="0204">Since the fluorescence measurement with respect to the second target detection step has been carried out at 95 Centigrade and 55 Centigrade which is lower than the Tm value of NG QP, it has been estimated that extinction of both of CT QP and the NG QP has been simultaneously detected according to measured values at the second target detection step.</p>
<p id="p0205" num="0205">Regarding an amplification curve of the negative reference, extinction has not observed until 44 cycles when the PCR ends. This is because a value 0.998 of F44 is not lower than a value 0.996 of Threshold 11. At this time, "mean - 3SD" is equal to 0 .996 to be regarded as Threshold 11 for the first target detection in this Embodiment, thereby being shown in Table 21. The amplification curve related thereto is also shown in <figref idref="f0013">Fig. 26</figref>.</p>
<p id="p0206" num="0206">Regarding another amplification curve of the pCT plasmid of the first target nucleic acid, extinction caused by annealing of CT QP has been observed from about 28 cycles. It has been revealed that a value 0.720 of F44 has been lower than Threshold 11, and further that the objective region of the pCT plasmid has been amplified.</p>
<p id="p0207" num="0207">At this time, "mean - 3SD" of Fs has been equal to -0.039 to be regarded as Threshold 12 for the second target detection, thereby being shown in Table 21. The amplification curve related thereto is also shown in <figref idref="f0014">Fig. 27</figref>.</p>
<p id="p0208" num="0208">Regarding an amplification curve of the pNG plasmid of the second target nucleic acid, no extinction has been observed during the amplification reaction. This is because a value 0.998 of F44 is not lower than a value 0.996 of Threshold 11. A value -0.065 of Fs<!-- EPO <DP n="45"> --> has been lower than Threshold 12.</p>
<p id="p0209" num="0209">The above-mentioned results have revealed that the objective region of the pCT plasmid has been not amplified, further that the objective region of the pNG plasmid has been amplified. Table 21 shows the value of the Fs. The amplification curve is shown in <figref idref="f0014">Fig. 28</figref>.
<tables id="tabl0021" num="0021">
<table frame="bottom">
<title>(Table 21)</title>
<tgroup cols="5" colsep="0">
<colspec colnum="1" colname="col1" colwidth="33mm"/>
<colspec colnum="2" colname="col2" colwidth="20mm"/>
<colspec colnum="3" colname="col3" colwidth="20mm"/>
<colspec colnum="4" colname="col4" colwidth="18mm"/>
<colspec colnum="5" colname="col5" colwidth="18mm"/>
<thead>
<row>
<entry namest="col1" nameend="col5" align="left" valign="top">Values used for determination of second item in QProbe method</entry></row>
<row>
<entry valign="top"/>
<entry align="center" valign="top">TE</entry>
<entry align="center" valign="top">pCT</entry>
<entry align="center" valign="top">pNG</entry>
<entry align="center" valign="top">pCT pNG</entry></row></thead>
<tbody>
<row>
<entry>F44</entry>
<entry align="center">0.998</entry>
<entry align="center">0.720</entry>
<entry align="center">0.998</entry>
<entry align="center">0.729</entry></row>
<row>
<entry>F44 (Average - 3SD)</entry>
<entry align="center">0. 996 <img id="ib0028" file="imgb0006.tif" wi="4" he="4" img-content="character" img-format="tif" inline="yes"/>1</entry>
<entry align="center">-</entry>
<entry align="center">-</entry>
<entry align="center">-</entry></row>
<row>
<entry>Fe</entry>
<entry align="center">1.009</entry>
<entry align="center">0.681</entry>
<entry align="center">0.933</entry>
<entry align="center">0.618</entry></row>
<row>
<entry>Fs</entry>
<entry align="center">0.011</entry>
<entry align="center">- 0.039</entry>
<entry align="center">- 0.065</entry>
<entry align="center">- 0.111</entry></row>
<row>
<entry>Fs (Average - 3SD)</entry>
<entry align="center">-</entry>
<entry align="center">0.039 <img id="ib0029" file="imgb0006.tif" wi="4" he="4" img-content="character" img-format="tif" inline="yes"/>2</entry>
<entry align="center">-</entry>
<entry align="center">-</entry></row></tbody></tgroup>
<tgroup cols="5" rowsep="0">
<colspec colnum="1" colname="col1" colwidth="33mm"/>
<colspec colnum="2" colname="col2" colwidth="20mm"/>
<colspec colnum="3" colname="col3" colwidth="20mm"/>
<colspec colnum="4" colname="col4" colwidth="18mm"/>
<colspec colnum="5" colname="col5" colwidth="18mm"/>
<tbody>
<row>
<entry namest="col1" nameend="col5" align="justify"><img id="ib0030" file="imgb0006.tif" wi="4" he="4" img-content="character" img-format="tif" inline="yes"/> 1 Threshold 11 <img id="ib0031" file="imgb0006.tif" wi="4" he="4" img-content="character" img-format="tif" inline="yes"/>2 Threshold 12</entry></row></tbody></tgroup>
</table>
</tables></p>
<p id="p0210" num="0210">Regarding an amplification curve upon both the pCT plasmid of the first target nucleic acid and the pNG plasmid of the second target nucleic acid have been added to the solution, extinction caused by annealing of CT QP has been observed from about 28 cycles as the same as the above-mentioned amplification curve of the pCT plasmid. A value 0.729 of F44 has been lower than Threshold 11, and it has been revealed that the objective region of the pCT plasmid has been amplified.</p>
<p id="p0211" num="0211">A value -0.111 of Fs is lower than Threshold 12, and it has been revealed that the objective region of the pNG plasmid has been amplified. Table 21 shows the value of the Fs. The amplification curve related thereto is shown in <figref idref="f0015">Fig. 29</figref>.</p>
<p id="p0212" num="0212">According to the above-mentioned results, it has been revealed that <i>Mycoplasma pneumoniae</i> P1 genes and internal control composition can be detected by means of one<!-- EPO <DP n="46"> --> reaction vessel containing one kind of reaction solution and one kind of fluorescent labels when the method of designing probes and temperature profiles are incorporated with two items of genes.</p>
<heading id="h0030">(Embodiment 7)</heading>
<heading id="h0031">&lt;Detection of <i>Mycoplasma pneumoniae</i> P1 genes and internal control composition based on QProbe method to detect plural times the second target in amplification reaction&gt;</heading>
<p id="p0213" num="0213">Not only after the final cycle but also during the amplification reaction, the second target detection step has been carried out in an inserted manner, and detection of <i>Mycoplasma pneumoniae</i> P1 genes and internal control composition has been performed based on the QProbe method.</p>
<p id="p0214" num="0214">The primers, probes, reaction solution composition, and nucleic acids have been used for the PCR method as the same as Embodiment 1. Table 22 shows reaction conditions thereof.<!-- EPO <DP n="47"> -->
<tables id="tabl0022" num="0022">
<table frame="bottom">
<title>(Table 22)</title>
<tgroup cols="4" colsep="0">
<colspec colnum="1" colname="col1" colwidth="60mm"/>
<colspec colnum="2" colname="col2" colwidth="26mm"/>
<colspec colnum="3" colname="col3" colwidth="26mm"/>
<colspec colnum="4" colname="col4" colwidth="38mm"/>
<tbody>
<row>
<entry namest="col1" nameend="col4" align="left" valign="middle">Reaction conditions of second target detecting step in QProbe method in Embodiment 7</entry></row></tbody></tgroup>
<tgroup cols="4" colsep="0">
<colspec colnum="1" colname="col1" colwidth="60mm"/>
<colspec colnum="2" colname="col2" colwidth="26mm"/>
<colspec colnum="3" colname="col3" colwidth="26mm"/>
<colspec colnum="4" colname="col4" colwidth="38mm"/>
<thead>
<row>
<entry align="center" valign="middle">Reaction steps</entry>
<entry namest="col2" nameend="col3" align="left" valign="middle">Temperature(°C)</entry>
<entry valign="middle">Time(s)</entry></row></thead>
<tbody>
<row>
<entry align="center" valign="middle">Initial denaturation</entry>
<entry valign="middle">95</entry>
<entry valign="middle">T<sub>0</sub></entry>
<entry valign="middle">120</entry></row>
<row rowsep="0">
<entry morerows="2" rowsep="1" align="center" valign="middle">Amplification (1 - 20 cycles)</entry>
<entry valign="middle">95</entry>
<entry valign="middle">T<sub>0</sub></entry>
<entry valign="middle">10 (FL measurement)</entry></row>
<row rowsep="0">
<entry valign="middle">70</entry>
<entry valign="middle">T<sub>1</sub></entry>
<entry valign="middle">10</entry></row>
<row>
<entry valign="middle">72</entry>
<entry valign="middle">T<sub>2</sub></entry>
<entry valign="middle">10 (FL measurement)</entry></row>
<row rowsep="0">
<entry morerows="1" rowsep="1" align="center" valign="middle">Second target NA detecting first time</entry>
<entry valign="middle">95</entry>
<entry valign="middle">T<sub>0</sub></entry>
<entry valign="middle">10 (FL measurement)</entry></row>
<row>
<entry valign="middle">55</entry>
<entry valign="middle">T<sub>3</sub></entry>
<entry valign="middle">10 (FL measurement)</entry></row>
<row rowsep="0">
<entry morerows="2" rowsep="1" align="center" valign="middle">Amplification (21 - 27 cycles)</entry>
<entry valign="middle">95</entry>
<entry valign="middle">T<sub>0</sub></entry>
<entry valign="middle">10 (FL measurement)</entry></row>
<row rowsep="0">
<entry valign="middle">7 0</entry>
<entry valign="middle">T<sub>1</sub></entry>
<entry valign="middle">10</entry></row>
<row>
<entry valign="middle">72</entry>
<entry valign="middle">T<sub>2</sub></entry>
<entry valign="middle">10 (FL measurement)</entry></row>
<row rowsep="0">
<entry morerows="1" rowsep="1" align="center" valign="middle">Second target NA detecting second time</entry>
<entry valign="middle">95</entry>
<entry valign="middle">T<sub>0</sub></entry>
<entry valign="middle">10 (FL measurement)</entry></row>
<row>
<entry valign="middle">55</entry>
<entry valign="middle">T<sub>3</sub></entry>
<entry valign="middle">10 (FL measurement)</entry></row>
<row rowsep="0">
<entry morerows="2" rowsep="1" align="center" valign="middle">Amplification (28 - 34 cycles)</entry>
<entry valign="middle">95</entry>
<entry valign="middle">T<sub>0</sub></entry>
<entry valign="middle">10 (FL measurement)</entry></row>
<row rowsep="0">
<entry valign="middle">70</entry>
<entry valign="middle">T<sub>1</sub></entry>
<entry valign="middle">10</entry></row>
<row>
<entry valign="middle">72</entry>
<entry valign="middle">T<sub>2</sub></entry>
<entry valign="middle">10 (FL measurement)</entry></row>
<row rowsep="0">
<entry morerows="1" rowsep="1" align="center" valign="middle">Second target NA detecting third time</entry>
<entry valign="middle">95</entry>
<entry valign="middle">T<sub>0</sub></entry>
<entry valign="middle">10 (FL measurement)</entry></row>
<row>
<entry valign="middle">55</entry>
<entry valign="middle">T<sub>3</sub></entry>
<entry valign="middle">10 (FL measurement)</entry></row>
<row rowsep="0">
<entry morerows="2" rowsep="1" align="center" valign="middle">Amplification (35 - 41 cycles)</entry>
<entry valign="middle">95</entry>
<entry valign="middle">T<sub>0</sub></entry>
<entry valign="middle">10 (FL measurement)</entry></row>
<row rowsep="0">
<entry valign="middle">70</entry>
<entry valign="middle">T<sub>1</sub></entry>
<entry valign="middle">10</entry></row>
<row>
<entry valign="middle">72</entry>
<entry valign="middle">T<sub>2</sub></entry>
<entry valign="middle">10 (FL measurement)</entry></row>
<row rowsep="0">
<entry morerows="1" rowsep="1" align="center" valign="middle">Second target NA detecting fourth time</entry>
<entry valign="middle">95</entry>
<entry valign="middle">T<sub>0</sub></entry>
<entry valign="middle">10 (FL measurement)</entry></row>
<row>
<entry valign="middle">55</entry>
<entry valign="middle">T<sub>3</sub></entry>
<entry valign="middle">10 (FL measurement)</entry></row></tbody></tgroup>
</table>
</tables></p>
<p id="p0215" num="0215"><figref idref="f0015">Fig. 30</figref> is a graph of changes of temperature in the amplification reaction.<!-- EPO <DP n="48"> --></p>
<p id="p0216" num="0216">In analysis of Embodiment 7, the same steps as Embodiment 1 except the following calculation have been carried out. <maths id="math0008" num="(Formula 4)"><math display="block"><mi>fen</mi><mo>=</mo><mi>fhyb</mi><mi>.en</mi><mo>/</mo><mi>fden</mi><mi>.en</mi></math><img id="ib0032" file="imgb0032.tif" wi="67" he="5" img-content="math" img-format="tif"/></maths> herein,
<ul id="ul0005" list-style="none" compact="compact">
<li>fen: fluorescence intensity value in n times second target detection step calculated according to Formula 4;</li>
<li>fhyb.en: fluorescence intensity value (55 Centigrade) in n times second target detection step; and</li>
<li>fden.en: fluorescence intensity value (95 Centigrade) in n times second target detection step.</li>
</ul>
<maths id="math0009" num="(Formula 5)"><math display="block"><mi>Fen</mi><mo>=</mo><mi>fen</mi><mo>/</mo><mi mathvariant="normal">f</mi><mn>10</mn></math><img id="ib0033" file="imgb0033.tif" wi="67" he="5" img-content="math" img-format="tif"/></maths> herein,<br/>
Fen: relative value in n times second target detection step assuming that the fluorescence intensity value in the tenth cycle obtained according to Formula 4 is equal to a value of "1." <maths id="math0010" num="(Formula 6)"><math display="block"><mi>Fs1</mi><mo>=</mo><mi>Fe1</mi><mo>−</mo><mi>F20</mi></math><img id="ib0034" file="imgb0034.tif" wi="67" he="5" img-content="math" img-format="tif"/></maths> <maths id="math0011" num="(Formula 6')"><math display="block"><mi>Fs2</mi><mo>=</mo><mi>Fe2</mi><mo>−</mo><mi>F27</mi></math><img id="ib0035" file="imgb0035.tif" wi="68" he="5" img-content="math" img-format="tif"/></maths> <maths id="math0012" num="(Formula 6&quot;)"><math display="block"><mi>Fs3</mi><mo>=</mo><mi>Fe3</mi><mo>−</mo><mi>F34</mi></math><img id="ib0036" file="imgb0036.tif" wi="70" he="5" img-content="math" img-format="tif"/></maths> <maths id="math0013" num="(Formula 6''')"><math display="block"><mi>Fs4</mi><mo>=</mo><mi>Fe4</mi><mo>−</mo><mi>F41</mi></math><img id="ib0037" file="imgb0037.tif" wi="71" he="5" img-content="math" img-format="tif"/></maths> herein,
<dl id="dl0001" compact="compact">
<dt>Fs1:</dt><dd>measurement value in first time second target detection step;</dd>
<dt>Fs2:</dt><dd>measurement value in second time second target detection step;</dd>
<dt>Fs3:</dt><dd>measurement value in third time second target detection step; and</dd>
<dt>Fs4:</dt><dd>measurement value in fourth time second target detection step.</dd>
</dl></p>
<p id="p0217" num="0217">Determination has been performed using the method shown below.<!-- EPO <DP n="49"> --></p>
<p id="p0218" num="0218">The F41 value of the measurement sample has been compared with Threshold 13. And, when the F41 value of the measurement sample is lower than Threshold 13, it has been determined that the first target nucleic acid is positive (existence), otherwise negative (nonexistence).</p>
<p id="p0219" num="0219">As Threshold 13, an average of F41 values of the negative reference minus three times the standard deviation (hereinafter, called as "mean - 3SD") has been used.</p>
<p id="p0220" num="0220">In the first time second target detection step, the Fs1 value has been compared with Threshold 14, and when the Fs1 value is lower than Threshold 14, it has been determined that the second target nucleic acid is positive (existence), otherwise negative (nonexistence).</p>
<p id="p0221" num="0221">As Threshold 14, the value of "mean - 3SD" regarding the Fs1 value of a sample to which only the pMYC plasmid is added has been used.</p>
<p id="p0222" num="0222">In the second time second target detection step, the Fs2 value has been compared with Threshold 15, and when the Fs2 value is lower than Threshold 15 it has been determined that the second target nucleic acid is positive (existence), otherwise negative (nonexistence).</p>
<p id="p0223" num="0223">As Threshold 15, the value of "mean - 3SD" regarding the Fs2 value of a sample to which only the pMYC plasmid is added has been used.</p>
<p id="p0224" num="0224">In the third time second target detection step, the Fs3 value has been compared with Threshold 16, and when the Fs3 value is lower than Threshold 16 it has been determined that the second target nucleic acid is positive (existence), otherwise negative (nonexistence).<!-- EPO <DP n="50"> --></p>
<p id="p0225" num="0225">As Threshold 16, the value of "mean - 3SD" regarding the Fs3 value of a sample to which only the pMYC plasmid is added has been used.</p>
<p id="p0226" num="0226">In the fourth time second target detection step, the Fs4 value has been compared with Threshold 17, and when the Fs4 value is lower than Threshold 17 it has been determined that the second target nucleic acid is positive (existence), otherwise negative (nonexistence).</p>
<p id="p0227" num="0227">As Threshold 17, the value of "mean - 3SD" regarding the Fs4 value of a sample to which only the pMYC plasmid is added has been used.</p>
<p id="p0228" num="0228">Regarding an amplification curve of the negative reference, extinction has not observed until 41 cycles when the PCR ends. This is because a value 0.999 of F41 is not lower than a value 0.998 of Threshold 13. At this time, "mean - 3SD" is equal to 0 .998 to be regarded as Threshold 13 for the first target detection in this Embodiment, thereby being shown in Table 23. The amplification curve related thereto is also shown in <figref idref="f0016">Fig. 31</figref>.</p>
<p id="p0229" num="0229">Regarding another amplification curve of the pMYC plasmid of the first target nucleic acid, extinction caused by annealing of MYC QP has been observed from about 30 cycles. It has been revealed that a value 0.892 of F41 has been lower than Threshold 13, and further that the objective region of the pMYC plasmid has been amplified.</p>
<p id="p0230" num="0230">At this time, "mean - 3SD" of Fs1 has been equal to -0.058, "mean - 3SD" of Fs2 has been equal to -0.070, "mean - 3SD" of Fs3 has been equal to -0.080, and "mean - 3SD" of Fs4 has been equal to -0.087 to be regarded as Threshold 14, Threshold 15, Threshold 16, and Threshold 17 for the second target detection, respectively, thereby<!-- EPO <DP n="51"> --> being shown in Table 23. The amplification curve related thereto is also shown in <figref idref="f0016">Fig. 32</figref>.
<tables id="tabl0023" num="0023">
<table frame="bottom">
<title>(Table 23)</title>
<tgroup cols="5" colsep="0">
<colspec colnum="1" colname="col1" colwidth="33mm"/>
<colspec colnum="2" colname="col2" colwidth="26mm"/>
<colspec colnum="3" colname="col3" colwidth="27mm"/>
<colspec colnum="4" colname="col4" colwidth="27mm"/>
<colspec colnum="5" colname="col5" colwidth="27mm"/>
<thead>
<row>
<entry namest="col1" nameend="col5" align="left" valign="top">Values used for determination at second target detecting step in QProbe method in Embodiment 7</entry></row>
<row>
<entry valign="top"/>
<entry align="center" valign="top">TE</entry>
<entry align="center" valign="top">pMYC</entry>
<entry align="center" valign="top">pICM5</entry>
<entry align="center" valign="top">pMYC pICM5</entry></row></thead>
<tbody>
<row>
<entry>F20</entry>
<entry align="center">0.999</entry>
<entry align="center">0.999</entry>
<entry align="center">0.999</entry>
<entry align="center">0.999</entry></row>
<row>
<entry>Fe1</entry>
<entry align="center">0.941</entry>
<entry align="center">0.941</entry>
<entry align="center">0.941</entry>
<entry align="center">0.941</entry></row>
<row>
<entry>Fs1</entry>
<entry align="center">-0.058</entry>
<entry align="center">-0.058</entry>
<entry align="center">-0.058</entry>
<entry align="center">-0.058</entry></row>
<row>
<entry>Fs1 (Average - 3SD)</entry>
<entry align="center">-</entry>
<entry align="center">-0.058 <img id="ib0038" file="imgb0006.tif" wi="4" he="4" img-content="character" img-format="tif" inline="yes"/>2</entry>
<entry align="center">-</entry>
<entry align="center">-</entry></row>
<row>
<entry>F27</entry>
<entry align="center">0.999</entry>
<entry align="center">0.999</entry>
<entry align="center">1.000</entry>
<entry align="center">0.999</entry></row>
<row>
<entry>Fe2</entry>
<entry align="center">0.941</entry>
<entry align="center">0.930</entry>
<entry align="center">0.943</entry>
<entry align="center">0.930</entry></row>
<row>
<entry>Fs2</entry>
<entry align="center">-0.058</entry>
<entry align="center">-0.068</entry>
<entry align="center">-0.057</entry>
<entry align="center">- 0.068</entry></row>
<row>
<entry>Fs2 (Average - 3SD)</entry>
<entry align="center">-</entry>
<entry align="center">-0.070 <img id="ib0039" file="imgb0006.tif" wi="4" he="4" img-content="character" img-format="tif" inline="yes"/>3</entry>
<entry align="center">-</entry>
<entry align="center">-</entry></row>
<row>
<entry>F34</entry>
<entry align="center">0.999</entry>
<entry align="center">0.949</entry>
<entry align="center">1.000</entry>
<entry align="center">0.951</entry></row>
<row>
<entry>Fe3</entry>
<entry align="center">0.941</entry>
<entry align="center">0.870</entry>
<entry align="center">0.916</entry>
<entry align="center">0.842</entry></row>
<row>
<entry>Fs3</entry>
<entry align="center">-0.058</entry>
<entry align="center">-0.079</entry>
<entry align="center">-0.084</entry>
<entry align="center">- 0.109</entry></row>
<row>
<entry>Fs3 (Average - 3SD)</entry>
<entry align="center"/>
<entry align="center">-0.080 <img id="ib0040" file="imgb0006.tif" wi="4" he="4" img-content="character" img-format="tif" inline="yes"/>4</entry>
<entry align="center">-</entry>
<entry align="center">-</entry></row>
<row>
<entry>F41</entry>
<entry align="center">0.999</entry>
<entry align="center">0.892</entry>
<entry align="center">0.999</entry>
<entry align="center">0.897</entry></row>
<row>
<entry>F41 (Average - 3SD)</entry>
<entry align="center">0.998 <img id="ib0041" file="imgb0006.tif" wi="4" he="4" img-content="character" img-format="tif" inline="yes"/>1</entry>
<entry align="center">-</entry>
<entry align="center">-</entry>
<entry align="center">-</entry></row>
<row>
<entry>Fe4</entry>
<entry align="center">0.940</entry>
<entry align="center">0.812</entry>
<entry align="center">0.805</entry>
<entry align="center">0.743</entry></row>
<row>
<entry>Fs4</entry>
<entry align="center">-0.058</entry>
<entry align="center">-0.080</entry>
<entry align="center">-0.192</entry>
<entry align="center">- 0.154</entry></row>
<row>
<entry>Fs4 (Average - 3SD)</entry>
<entry align="center">-</entry>
<entry align="center">-0.087 <img id="ib0042" file="imgb0006.tif" wi="4" he="4" img-content="character" img-format="tif" inline="yes"/>5</entry>
<entry align="center">-</entry>
<entry align="center">-</entry></row></tbody></tgroup>
<tgroup cols="5" rowsep="0">
<colspec colnum="1" colname="col1" colwidth="33mm"/>
<colspec colnum="2" colname="col2" colwidth="26mm"/>
<colspec colnum="3" colname="col3" colwidth="27mm"/>
<colspec colnum="4" colname="col4" colwidth="27mm"/>
<colspec colnum="5" colname="col5" colwidth="27mm"/>
<tbody>
<row>
<entry namest="col1" nameend="col5" align="justify"><img id="ib0043" file="imgb0006.tif" wi="4" he="4" img-content="character" img-format="tif" inline="yes"/> 1 Threshold 13 <img id="ib0044" file="imgb0006.tif" wi="4" he="4" img-content="character" img-format="tif" inline="yes"/>2 Threshold 14 <img id="ib0045" file="imgb0006.tif" wi="4" he="4" img-content="character" img-format="tif" inline="yes"/>3 Threshold 15<br/>
<img id="ib0046" file="imgb0006.tif" wi="4" he="4" img-content="character" img-format="tif" inline="yes"/> 4 Threshold 16 <img id="ib0047" file="imgb0006.tif" wi="4" he="4" img-content="character" img-format="tif" inline="yes"/>5 Threshold 17</entry></row></tbody></tgroup>
</table>
</tables></p>
<p id="p0231" num="0231">Regarding an amplification curve of the pICM5 plasmid of the second target nucleic acid, no extinction has been observed during the amplification reaction except in the respective second target detection steps. This is because a value 0.999 of F41 is not lower than a value 0.998 of Threshold 13. A value -0.058 of Fs1 has been higher than Threshold 14, and it has been revealed that the objective region of the pICM5 plasmid has not been amplified up to an identification limit until the first time second target detection step.</p>
<p id="p0232" num="0232"><!-- EPO <DP n="52"> --> A value -0.057 of Fs2 has been higher than Threshold 15, and it has been revealed that the objective region of the pICM5 plasmid has not been amplified up to the identification limit until the second time second target detection step.</p>
<p id="p0233" num="0233">A value -0.084 of Fs3 has been lower than Threshold 16, and it has been revealed that the objective region of the pICM5 plasmid has been amplified beyond the identification limit until the third time second target detection step.</p>
<p id="p0234" num="0234">A value -0.192 of Fs4 has also been lower than Threshold 17. Table 23 shows the values of the Fs1, Fs2, Fs3 and Fs4. The amplification curves are shown in <figref idref="f0017">Fig. 33</figref>.</p>
<p id="p0235" num="0235">Regarding an amplification curve upon both the pMYC plasmid of the first target nucleic acid and the pICM5 plasmid of the second target nucleic acid have been added to the solution, extinction caused by annealing of MYC QP has been observed from about 30 cycles as the same as the amplification curve of the pMYC plasmid. A value 0.897 of F41 has been lower than Threshold 13, and it has been revealed that the objective region of the pMYC plasmid has been amplified.</p>
<p id="p0236" num="0236">A value -0.058 of Fs1 has been higher than Threshold 14, and it has been revealed that the objective region of the pICM5 plasmid has not been amplified beyond the identification limit until the first time second target detection step.</p>
<p id="p0237" num="0237">A value -0.068 of Fs2 has been also higher than Threshold 15, and it has been revealed that the objective region of the pICM5 plasmid has not been amplified beyond the identification limit until the second time second target detection step.</p>
<p id="p0238" num="0238">A value -0.109 of Fs3 has been lower than Threshold 16, and it has been revealed that<!-- EPO <DP n="53"> --> the objective region of the pICM5 plasmid has been amplified beyond the identification limit until the third time second target detection step.</p>
<p id="p0239" num="0239">A value -0.154 of Fs4 has also been lower than Threshold 17. Table 23 shows the values of the Fs1, Fs2, Fs3 and Fs4. The amplification curves are shown in <figref idref="f0017">Fig. 34</figref>.</p>
<p id="p0240" num="0240">According to the above-mentioned results, also in a case where the second target detection step has been carried out in the inserted manner not only after the final cycle but also within the amplification reaction, it has been revealed that <i>Mycoplasma pneumoniae</i> P1 genes and internal control composition can be detected.</p>
<heading id="h0032">BRIEF DESCRIPTION OF THE DRAWINGS</heading>
<p id="p0241" num="0241">
<ul id="ul0006" list-style="none" compact="compact">
<li><figref idref="f0001">Fig. 1</figref> is a graph showing changes of temperature within mixed-solution in Embodiment 1 according to the present invention;</li>
<li><figref idref="f0001">Fig. 2</figref> is a timing explanatory diagram of fluorometry in Embodiment 1 according to the present invention;</li>
<li><figref idref="f0002">Fig. 3</figref> is a flow chart showing a determination method in Embodiment 1 according to the present invention;</li>
<li><figref idref="f0002">Fig. 4</figref> is a graph showing changes of fluorescence intensity regarding a negative reference in Embodiment 1 according to the present invention;</li>
<li><figref idref="f0003">Fig. 5</figref> is a graph showing changes of fluorescence intensity regarding a first target nucleic acid in Embodiment 1 according to the present invention;</li>
<li><figref idref="f0003">Fig. 6</figref> is a graph showing changes of fluorescence intensity regarding a second target nucleic acid in Embodiment 1 according to the present invention;</li>
<li><figref idref="f0004">Fig. 7</figref> is a graph showing changes of fluorescence intensity regarding the first target nucleic acid and the second target nucleic acid in Embodiment 1 according to the present invention;<!-- EPO <DP n="54"> --></li>
<li><figref idref="f0004">Fig. 8</figref> is a timing explanatory diagram of fluorometry in Embodiment 2 according to the present invention;</li>
<li><figref idref="f0005">Fig. 9</figref> is a graph showing changes of fluorescence intensity regarding a negative reference in Embodiment 2 according to the present invention;</li>
<li><figref idref="f0005">Fig. 10</figref> is a graph showing changes of fluorescence intensity regarding a first target nucleic acid in Embodiment 2 according to the present invention;</li>
<li><figref idref="f0006">Fig. 11</figref> is a graph showing changes fluorescence intensity regarding a second target nucleic acid in Embodiment 2 according to the present invention;</li>
<li><figref idref="f0006">Fig. 12</figref> is a graph showing changes of fluorescence intensity regarding the first target nucleic acid and the second target nucleic acid in Embodiment 2 according to the present invention;</li>
<li><figref idref="f0007">Fig. 13</figref> is a flow chart showing a determination method in Embodiment 3 according to the present invention;</li>
<li><figref idref="f0007">Fig. 14</figref> is a graph showing changes of fluorescence intensity regarding a negative reference in Embodiment 3 according to the present invention;</li>
<li><figref idref="f0008">Fig. 15</figref> is a graph showing changes of fluorescence intensity regarding a first target nucleic acid in Embodiment 3 according to the present invention;</li>
<li><figref idref="f0008">Fig. 16</figref> is a graph showing changes of fluorescence intensity regarding a second target nucleic acid in Embodiment 3 according to the present invention;</li>
<li><figref idref="f0009">Fig. 17</figref> is a graph showing changes of fluorescence intensity regarding the first target nucleic acid and the second target nucleic acid in Embodiment 3 according to the present invention;</li>
<li><figref idref="f0009">Fig. 18</figref> is a graph showing changes of fluorescence intensity regarding a negative reference in Embodiment 4 according to the present invention;</li>
<li><figref idref="f0010">Fig. 19</figref> is a graph showing changes of fluorescence intensity regarding a first target nucleic acid in Embodiment 4 according to the present invention;</li>
<li><figref idref="f0010">Fig. 20</figref> is a graph showing changes of fluorescence intensity regarding a second target<!-- EPO <DP n="55"> --> nucleic acid in Embodiment 4 according to the present invention;</li>
<li><figref idref="f0011">Fig. 21</figref> is a graph showing changes of fluorescence intensity regarding the first target nucleic acid and the second target nucleic acid in Embodiment 4 according to the present invention;</li>
<li><figref idref="f0011">Fig. 22</figref> is a graph showing changes of fluorescence intensity regarding a negative reference in Embodiment 5 according to the present invention;</li>
<li><figref idref="f0012">Fig. 23</figref> is a graph showing changes of fluorescence intensity regarding a first target nucleic acid in Embodiment 5 according to the present invention;</li>
<li><figref idref="f0012">Fig. 24</figref> is a graph showing changes of fluorescence intensity regarding a second target nucleic acid in Embodiment 5 according to the present invention;</li>
<li><figref idref="f0013">Fig. 25</figref> is a graph showing changes of fluorescence intensity regarding the first target nucleic acid and the second target nucleic acid in Embodiment 5 according to the present invention;</li>
<li><figref idref="f0013">Fig. 26</figref> is a graph showing changes of fluorescence intensity regarding a negative reference in Embodiment 6 according to the present invention;</li>
<li><figref idref="f0014">Fig. 27</figref> is a graph showing changes of fluorescence intensity regarding a first target nucleic acid in Embodiment 6 according to the present invention;</li>
<li><figref idref="f0014">Fig. 28</figref> is a graph showing changes of fluorescence intensity regarding a second target nucleic acid in Embodiment 6 according to the present invention;</li>
<li><figref idref="f0015">Fig. 29</figref> is a graph showing changes of fluorescence intensity regarding the first target nucleic acid and the second target nucleic acid in Embodiment 6 according to the present invention;</li>
<li><figref idref="f0015">Fig. 30</figref> is a graph showing changes of temperature within mixed-solution in Embodiment 7 according to the present invention;</li>
<li><figref idref="f0016">Fig. 31</figref> is a graph showing changes of fluorescence intensity regarding a negative reference in Embodiment 7 according to the present invention;</li>
<li><figref idref="f0016">Fig. 32</figref> is a graph showing changes of fluorescence intensity regarding a first target<!-- EPO <DP n="56"> --> nucleic acid in Embodiment 7 according to the present invention;</li>
<li><figref idref="f0017">Fig. 33</figref> is a graph showing changes of fluorescence intensity regarding a second target nucleic acid in Embodiment 7 according to the present invention;</li>
<li><figref idref="f0017">Fig. 34</figref> is a graph showing changes of fluorescence intensity regarding the first target nucleic acid and the second target nucleic acid in Embodiment 7 according to the present invention;</li>
<li><figref idref="f0018">Fig. 35</figref> is an enlarged view of changes of temperature in Embodiment 1 according to the present invention;</li>
<li><figref idref="f0019">Fig. 36</figref> is an explanatory diagram of mixed-solution composition in Embodiment 1 according to the present invention;</li>
<li><figref idref="f0020">Fig. 37(a)</figref> is an explanatory diagram of a denaturation step in Embodiment 1 according to the present invention;</li>
<li><figref idref="f0020">Fig. 37(b)</figref> is an explanatory diagram of an annealing step in Embodiment 1 according to the present invention;</li>
<li><figref idref="f0021">Fig. 37(c)</figref> is an explanatory diagram of an elongation step in Embodiment 1 according to the present invention;</li>
<li><figref idref="f0021">Fig. 37(d)</figref> is an explanatory diagram of an elongation-completed step in Embodiment 1 according to the present invention;</li>
<li><figref idref="f0022">Fig. 38(a)</figref> is an explanatory diagram of the denaturation step in Embodiment 1 according to the present invention; and</li>
<li><figref idref="f0022">Fig. 38(b)</figref> is an explanatory diagram of the annealing step in Embodiment 1 according to the present invention.</li>
</ul></p>
<heading id="h0033">BRIEF DESCRIPTION OF SYMBOLS</heading>
<p id="p0242" num="0242">
<dl id="dl0002">
<dt>1:</dt><dd>Vessel</dd>
<dt>2:</dt><dd>Solution</dd>
<dt>10:</dt><dd>First target nucleic acid<!-- EPO <DP n="57"> --></dd>
<dt>13:</dt><dd>First target's F-primer</dd>
<dt>14:</dt><dd>First target's R-primer</dd>
<dt>15:</dt><dd>First target's probe</dd>
<dt>16:</dt><dd>First labeling substance</dd>
<dt>20:</dt><dd>Second target nucleic acid</dd>
<dt>23:</dt><dd>Second target's F-primer</dd>
<dt>24:</dt><dd>Second target's R-primer</dd>
<dt>25:</dt><dd>Second target's probe</dd>
<dt>26:</dt><dd>Second labeling substance</dd>
<dt>30:</dt><dd>DNA polymerase</dd>
<dt>31:</dt><dd>Deoxyribonucleoside triphoshate</dd>
<dt>T0:</dt><dd>Denaturation temperature</dd>
<dt>T1:</dt><dd>Annealing temperature</dd>
<dt>T2:</dt><dd>Elongation temperature</dd>
<dt>T3:</dt><dd>Second target detection temperature</dd>
</dl><!-- EPO <DP n="58"> --></p>
<heading id="h0034">SEQUENCE LISTING</heading>
<p id="p0243" num="0243">
<ul id="ul0007" list-style="none">
<li>&lt;110&gt; Mizuho Medy Co., Ltd.</li>
<li>&lt;120&gt; A Kit to Detect Multiple Nucleic Acids, and Method for The Same</li>
<li>&lt;130&gt; MZM1501</li>
<li>&lt;140&gt; <patcit id="pcit0016" dnum="JP2015113979A"><text>JP2015-113979</text></patcit><br/>
&lt;141&gt; 2015-06-04</li>
<li>&lt;160&gt; 11</li>
<li>&lt;170&gt; PatentIn version 3.5</li>
<li>&lt;210&gt; 1<br/>
&lt;211&gt; 21<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Mycoplasma pneumoniae</li>
<li>&lt;400&gt; 1<br/>
gccaccctcg ggggcagtca g 21</li>
<li>&lt;210&gt; 2<br/>
&lt;211&gt; 22<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Mycoplasma pneumoniae</li>
<li>&lt;400&gt; 2<br/>
gagtcgggat tccccgcgga gg 22</li>
<li>&lt;210&gt; 3<br/>
&lt;211&gt; 26<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Mycoplasma pneumoniae</li>
<li>&lt;400&gt; 3<br/>
ccctcgacca agccaacctc cagctc 26</li>
<li>&lt;210&gt; 4<br/>
&lt;211&gt; 17<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; random sequence</li>
<li>&lt;400&gt; 4<br/>
agtgggactc accaacc 17</li>
<li>&lt;210&gt; 5<br/>
&lt;211&gt; 16<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial Sequence</li>
<li>&lt;220&gt;<br/>
&lt;223&gt; random sequence</li>
<li>&lt;400&gt; 5<br/>
<!-- EPO <DP n="59"> -->agtgggactc accaac 16</li>
<li>&lt;210&gt; 6<br/>
&lt;211&gt; 30<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Chlamydia trachomatis</li>
<li>&lt;400&gt; 6<br/>
tgagcaccct aggcgtttgt actccgtcac 30</li>
<li>&lt;210&gt; 7<br/>
&lt;211&gt; 36<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Chlamydia trachomatis</li>
<li>&lt;400&gt; 7<br/>
gcactttcta caagagtaca tcggtcaacg aagagg 36</li>
<li>&lt;210&gt; 8<br/>
&lt;211&gt; 25<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Neisseria gonorrhoeae</li>
<li>&lt;400&gt; 8<br/>
gggcgtggtt gaactggcaa aaagc 25</li>
<li>&lt;210&gt; 9<br/>
&lt;211&gt; 27<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Neisseria gonorrhoeae</li>
<li>&lt;400&gt; 9<br/>
cagtgatttt ggcattggcg atattgg 27</li>
<li>&lt;210&gt; 10<br/>
&lt;211&gt; 26<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Chlamydia trachomatis</li>
<li>&lt;400&gt; 10<br/>
tgcgggcgat ttgccttaac cccacc 26</li>
<li>&lt;210&gt; 11<br/>
&lt;211&gt; 25<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Neisseria gonorrhoeae</li>
<li>&lt;400&gt; 11<br/>
ctaagcaaaa ttcgaggggg aaaac 25</li>
</ul></p>
</description>
<claims id="claims01" lang="en"><!-- EPO <DP n="60"> -->
<claim id="c-en-01-0001" num="0001">
<claim-text>A method for together detecting multiple target nucleic acids differing from each other, the multiple target nucleic acids including a first target nucleic acid and a second target nucleic acid, the method using:
<claim-text>a solution being capable of containing the first target nucleic acid and the second target nucleic acid therein, at a denaturation temperature TO, first double-stranded hydrogen bond of the first target nucleic acid being cut off to be dissociate into first two single strands, second double-stranded hydrogen bond of the second target nucleic acid being cut off to be dissociate into second two single strands, respectively,</claim-text>
<claim-text>the solution further containing therein:
<claim-text>a first target's primer at an annealing temperature T1 specifically bonding with either of the first two single strands into which the first target nucleic acid has been dissociated;</claim-text>
<claim-text>a second target's primer at the annealing temperature T1 specifically bonding with either of the second two single strands into which the second target nucleic acid has been dissociated;</claim-text>
<claim-text>a first target's probe at the annealing temperature T1 specifically bonding with either of the first two single strands into which the first target nucleic acid has been dissociated, the first target's probe including a first labeling substance changing first fluorescent signals thereof when the first target's probe specifically bonds with either of the first two single strands;</claim-text>
<claim-text>DNA polymerase;</claim-text>
<claim-text>deoxyribonucleoside triphoshate at an elongation temperature T2 bonding by action of the DNA polymerase with both of the first two single strands into which the first target nucleic acid has been dissociated and the second two single strands into<!-- EPO <DP n="61"> --> which the second target nucleic acid has been dissociated; and</claim-text>
<claim-text>a second target's probe at the annealing temperature T1 bonding with neither the first two single strands into which the first target nucleic acid has been dissociated nor the second two single strands into which the second target nucleic acid has been dissociated, the second target's probe at a second target detection temperature T3 bonding with the second two single strands into which the second target nucleic acid has been dissociated, the second target's probe including a second labeling substance changing second fluorescent signals thereof when the second target's probe specifically bonds with either of the second two single strands,</claim-text></claim-text>
<claim-text>wherein
<claim-text>T0 is defined as the denaturation temperature; T1 is defined as the annealing temperature; T2 is defined as the elongation temperature; T3 is defined as the second target detection temperature, T0 through T3 being set up such that a condition that: T0&gt;T2≥T1&gt;T3 is satisfied; and</claim-text>
<claim-text>the first labeling substance and the second labeling substance are identical;</claim-text></claim-text>
<claim-text>wherein a difference caused by changes of the first and second fluorescent signals according to the second labeling substance is captured to judge existence or non existence of the second target nucleic acid.</claim-text></claim-text></claim>
<claim id="c-en-01-0002" num="0002">
<claim-text>The method for together detecting multiple target nucleic acids differing from each other as defined in claim 1, wherein the fluorescent signals are shown by quenching light when the annealing occurs.</claim-text></claim>
<claim id="c-en-01-0003" num="0003">
<claim-text>The method for together detecting multiple target nucleic acids differing from each other as defined in claim 1, wherein the fluorescent signals are shown by emitting light when the annealing occurs.<!-- EPO <DP n="62"> --></claim-text></claim>
<claim id="c-en-01-0004" num="0004">
<claim-text>The method for together detecting multiple target nucleic acids differing from each other as defined in any one of claim 1 to 3, wherein the first target nucleic acid is a <i>Mycoplasma pneumoniae</i> P1 gene and the second target nucleic acid is internal control composition.</claim-text></claim>
<claim id="c-en-01-0005" num="0005">
<claim-text>The method for together detecting multiple target nucleic acids differing from each other as defined in any one of claim 1 to 3, wherein the first target nucleic acid is a <i>Chlamydia trachomatis</i> endogeneous plasmid gene and the second target nucleic acid is a <i>Nisseria gonorrhoeae</i> CMT gene.</claim-text></claim>
</claims>
<claims id="claims02" lang="de"><!-- EPO <DP n="63"> -->
<claim id="c-de-01-0001" num="0001">
<claim-text>Verfahren zum gemeinsamen Nachweisen mehrerer Zielnukleinsäuren, die sich voneinander unterscheiden, wobei die mehreren Zielnukleinsäuren eine erste Zielnukleinsäure und eine zweite Zielnukleinsäure umfassen, wobei das Verfahren verwendet:
<claim-text>eine Lösung, die in der Lage ist, die erste Zielnukleinsäure und die zweite Zielnukleinsäure zu enthalten, wobei bei einer Denaturierungstemperatur T0 die erste doppelsträngige Wasserstoffbindung der ersten Zielnukleinsäure abgeschnitten wird, um entsprechend in zwei erste Einzelstränge dissoziiert zu werden, und die zweite doppelsträngige Wasserstoffbindung der zweiten Zielnukleinsäure abgeschnitten wird, um entsprechend in zwei zweite Einzelstränge dissoziiert zu werden,</claim-text>
<claim-text>wobei die Lösung ferner enthält:
<claim-text>einen ersten Zielprimer, der sich bei einer Annealing-Temperatur T1 spezifisch mit einem der zwei ersten Einzelstränge verbindet, in welche die erste Zielnukleinsäure dissoziiert wurde;</claim-text>
<claim-text>einen zweiten Zielprimer, der sich bei der Annealing-Temperatur T1 spezifisch mit einem der zwei zweiten Einzelstränge verbindet, in welche die zweite Zielnukleinsäure dissoziiert wurde;</claim-text>
<claim-text>eine erste Zielsonde, die sich bei der Annealing-Temperatur T1 spezifisch mit einem der zwei ersten Einzelstränge, in welche die erste Zielnukleinsäure dissoziiert wurde, verbindet, wobei die erste Zielsonde eine erste Markierungssubstanz enthält, die ihre ersten Fluoreszenzsignale verändert, wenn die erste Zielsonde sich spezifisch mit einem der zwei ersten Einzelstränge verbindet;</claim-text>
<claim-text>DNA-Polymerase;</claim-text>
<claim-text>Desoxyribonukleosidtriphosphat, das sich bei einer Elongationstemperatur T2 durch die Wirkung der DNA-Polymerase mit beiden der zwei ersten Einzelstränge, in welche die erste Zielnukleinsäure dissoziiert wurde, und den zwei zweiten Einzelsträngen, in welche die zweite Zielnukleinsäure dissoziiert wurde, verbindet; und</claim-text>
<claim-text>eine zweite Zielsonde, die sich bei der Annealing-Temperatur T1 weder mit den ersten zwei Einzelsträngen, in welche die erste Zielnukleinsäure dissoziiert wurde, noch mit den zweiten zwei Einzelsträngen, in welche die zweite Zielnukleinsäure dissoziiert<!-- EPO <DP n="64"> --> wurde, verbindet, wobei die zweite Zielsonde bei einer zweiten Zielnachweistemperatur T3 an die zweiten zwei Einzelstränge bindet, in welche die zweite Zielnukleinsäure dissoziiert wurde, wobei die zweite Zielsonde eine zweite Markierungssubstanz enthält, die ihre zweiten Fluoreszenzsignale verändert, wenn die zweite Zielsonde spezifisch an einen der zweiten zwei Einzelstränge bindet,</claim-text></claim-text>
<claim-text>wobei
<claim-text>T0 als die Denaturierungstemperatur definiert ist; T1 als die Annealing-Temperatur definiert ist; T2 als die Elongationstemperatur definiert ist; T3 als die zweite Zielnachweistemperatur definiert ist, wobei T0 bis T3 so eingestellt sind, dass eine Bedingung, dass: Ta&gt;T2≥T1&gt;T3 erfüllt ist; und</claim-text>
<claim-text>die erste Markierungssubstanz und die zweite Markierungssubstanz identisch sind;</claim-text></claim-text>
<claim-text>wobei ein Unterschied, der durch Änderungen der ersten und zweiten Fluoreszenzsignale entsprechend der zweiten Markierungssubstanz verursacht wird, erfasst wird, um das Vorhandensein oder Nichtvorhandensein der zweiten Zielnukleinsäure zu beurteilen.</claim-text></claim-text></claim>
<claim id="c-de-01-0002" num="0002">
<claim-text>Verfahren zum gemeinsamen Nachweisen mehrerer Zielnukleinsäuren, die sich voneinander unterscheiden, wie in Anspruch 1 definiert, wobei die Fluoreszenzsignale durch Quenchen von Licht gezeigt werden, wenn das Annealing stattfindet.</claim-text></claim>
<claim id="c-de-01-0003" num="0003">
<claim-text>Verfahren zum gemeinsamen Nachweisen mehrerer Zielnukleinsäuren, die sich voneinander unterscheiden, wie in Anspruch 1 definiert, wobei die Fluoreszenzsignale durch Emittieren von Licht gezeigt werden, wenn das Annealing stattfindet.</claim-text></claim>
<claim id="c-de-01-0004" num="0004">
<claim-text>Verfahren zum gemeinsamen Nachweisen mehrerer Zielnukleinsäuren, die sich voneinander unterscheiden, wie in einem der Ansprüche 1 bis 3 definiert, wobei die erste Zielnukleinsäure ein <i>Mycoplasma pneumoniae</i> P1-Gen und die zweite Zielnukleinsäure eine interne Kontrollzusammensetzung ist.<!-- EPO <DP n="65"> --></claim-text></claim>
<claim id="c-de-01-0005" num="0005">
<claim-text>Verfahren zum gemeinsamen Nachweisen mehrerer Zielnukleinsäuren, die sich voneinander unterscheiden, wie in einem der Ansprüche 1 bis 3 definiert, wobei die erste Zielnukleinsäure ein endogenes <i>Chlamydia</i> trachomatis-Plasmidgen ist und die zweite Zielnukleinsäure ein <i>Nisseria gonorrhoeae</i> CMT-Gen ist.</claim-text></claim>
</claims>
<claims id="claims03" lang="fr"><!-- EPO <DP n="66"> -->
<claim id="c-fr-01-0001" num="0001">
<claim-text>Procédé de détection conjointe de multiples acides nucléiques cibles différant les uns des autres, les multiples acides nucléiques cibles incluant un premier acide nucléique cible et un second acide nucléique cible, le procédé utilisant :
<claim-text>une solution en mesure de contenir le premier acide nucléique cible et le second acide nucléique cible dans celle-ci, à une température de dénaturation T0, respectivement, une première liaison d'hydrogène double brin du premier acide nucléique cible étant coupée pour être dissociée en deux premiers simples brins, une seconde liaison d'hydrogène double brin du second acide nucléique cible étant coupée pour être dissociée en deux seconds simples brins,</claim-text>
<claim-text>la solution contenant en outre dans celle-ci :
<claim-text>une amorce de la première cible à une température de fusion T1 se liant spécifiquement à l'un quelconque des deux premiers simples brins en lesquels le premier acide nucléique cible a été dissocié ;</claim-text>
<claim-text>une amorce de la seconde cible à une température de fusion T1 se liant spécifiquement à l'un quelconque des deux seconds simples brins en lesquels le second acide nucléique cible a été dissocié ;</claim-text>
<claim-text>une sonde de la première cible à une température de fusion T1 se liant spécifiquement à l'un quelconque des deux premiers simples brins en lesquels le premier acide nucléique cible a été dissocié, la sonde de la première cible incluant une première substance de marquage modifiant des premiers signaux fluorescents de celle-ci lorsque la sonde de la cible première se lie spécifiquement à l'un quelconque des deux premiers simples brins ;</claim-text>
<claim-text>une ADN polymérase;</claim-text>
<claim-text>un désoxyribonucléoside triphosphate à une température d'allongement T2 se liant par l'action de l'ADN polymérase à la fois aux deux premiers simples brins en lesquels le premier acide nucléique cible a été dissocié et aux deux seconds simples brins en lesquels le second acide nucléique cible a été dissocié ; et</claim-text>
<claim-text>une sonde de la seconde cible à une température de fusion T1 se liant ni aux deux premiers simples brins en lesquels le premier acide nucléique cible a été dissocié ni aux deux seconds simples brins en lesquels le second acide nucléique cible a été dissocié, la sonde de la seconde cible à une seconde température de détection de cible T3 se liant<!-- EPO <DP n="67"> --> aux deux seconds simples brins en lesquels le second acide nucléique cible a été dissocié, la sonde de la seconde cible incluant une seconde substance de marquage modifiant des seconds signaux fluorescents de celle-ci lorsque la sonde de la seconde cible se lie spécifiquement à l'un quelconque des deux seconds simples brins,</claim-text></claim-text>
<claim-text>dans lequel<br/>
T0 est défini comme la température de dénaturation ; T1 est défini comme la température de fusion ; T2 est défini comme la température d'allongement ; T3 est défini comme la température de détection de seconde cible, T0 à T3 étant établis de sorte qu'une condition selon laquelle :
<claim-text>T0&gt;T2≥T1&gt;T3 est remplie ; et</claim-text>
<claim-text>la première substance de marquage et la seconde substance de marquage sont identiques ;</claim-text></claim-text>
<claim-text>dans lequel une différence due à des modifications des premier et second signaux fluorescents selon la seconde substance de marquage est saisie afin d'évaluer l'existence ou non du second acide nucléique cible.</claim-text></claim-text></claim>
<claim id="c-fr-01-0002" num="0002">
<claim-text>Procédé de détection conjointe de multiples acides nucléiques cibles différant les uns des autres tel que défini selon la revendication 1, dans lequel les signaux fluorescents sont montrés par une extinction de lumière lorsque la fusion a lieu.</claim-text></claim>
<claim id="c-fr-01-0003" num="0003">
<claim-text>Procédé de détection conjointe de multiples acides nucléiques cibles différant les uns des autres tel que défini selon la revendication 1, dans lequel les signaux fluorescents sont montrés par une émission de lumière lorsque la fusion a lieu.</claim-text></claim>
<claim id="c-fr-01-0004" num="0004">
<claim-text>Procédé de détection conjointe de multiples acides nucléiques cibles différant les uns des autres tel que défini selon l'une quelconque des revendications 1 à 3, dans lequel le premier acide nucléique cible est un gène P1 de <i>Mycoplasma pneumoniae</i> et le second acide nucléique cible est une composition témoin interne.</claim-text></claim>
<claim id="c-fr-01-0005" num="0005">
<claim-text>Procédé de détection conjointe de multiples acides nucléiques cibles différant les uns des autres tel que défini selon l'une quelconque des revendications 1 à 3, dans lequel le premier acide nucléique cible est un gène plasmidique endogène de <i>Chlamydia trachomatis</i> et le second acide nucléique cible est un gène CMT de <i>Nisseria gonorrhoeae.</i></claim-text></claim>
</claims>
<drawings id="draw" lang="en"><!-- EPO <DP n="68"> -->
<figure id="f0001" num="1,2"><img id="if0001" file="imgf0001.tif" wi="165" he="211" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="69"> -->
<figure id="f0002" num="3,4"><img id="if0002" file="imgf0002.tif" wi="162" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="70"> -->
<figure id="f0003" num="5,6"><img id="if0003" file="imgf0003.tif" wi="155" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="71"> -->
<figure id="f0004" num="7,8"><img id="if0004" file="imgf0004.tif" wi="164" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="72"> -->
<figure id="f0005" num="9,10"><img id="if0005" file="imgf0005.tif" wi="157" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="73"> -->
<figure id="f0006" num="11,12"><img id="if0006" file="imgf0006.tif" wi="156" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="74"> -->
<figure id="f0007" num="13,14"><img id="if0007" file="imgf0007.tif" wi="162" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="75"> -->
<figure id="f0008" num="15,16"><img id="if0008" file="imgf0008.tif" wi="154" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="76"> -->
<figure id="f0009" num="17,18"><img id="if0009" file="imgf0009.tif" wi="155" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="77"> -->
<figure id="f0010" num="19,20"><img id="if0010" file="imgf0010.tif" wi="155" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="78"> -->
<figure id="f0011" num="21,22"><img id="if0011" file="imgf0011.tif" wi="155" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="79"> -->
<figure id="f0012" num="23,24"><img id="if0012" file="imgf0012.tif" wi="154" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="80"> -->
<figure id="f0013" num="25,26"><img id="if0013" file="imgf0013.tif" wi="155" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="81"> -->
<figure id="f0014" num="27,28"><img id="if0014" file="imgf0014.tif" wi="154" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="82"> -->
<figure id="f0015" num="29,30"><img id="if0015" file="imgf0015.tif" wi="165" he="229" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="83"> -->
<figure id="f0016" num="31,32"><img id="if0016" file="imgf0016.tif" wi="154" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="84"> -->
<figure id="f0017" num="33,34"><img id="if0017" file="imgf0017.tif" wi="153" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="85"> -->
<figure id="f0018" num="35"><img id="if0018" file="imgf0018.tif" wi="145" he="102" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="86"> -->
<figure id="f0019" num="36"><img id="if0019" file="imgf0019.tif" wi="133" he="144" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="87"> -->
<figure id="f0020" num="37(a),37(b)"><img id="if0020" file="imgf0020.tif" wi="94" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="88"> -->
<figure id="f0021" num="37(c),37(d)"><img id="if0021" file="imgf0021.tif" wi="95" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="89"> -->
<figure id="f0022" num="38(a),38(b)"><img id="if0022" file="imgf0022.tif" wi="113" he="213" img-content="drawing" img-format="tif"/></figure>
</drawings>
<ep-reference-list id="ref-list">
<heading id="ref-h0001"><b>REFERENCES CITED IN THE DESCRIPTION</b></heading>
<p id="ref-p0001" num=""><i>This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.</i></p>
<heading id="ref-h0002"><b>Patent documents cited in the description</b></heading>
<p id="ref-p0002" num="">
<ul id="ref-ul0001" list-style="bullet">
<li><patcit id="ref-pcit0001" dnum="JP2002136300A"><document-id><country>JP</country><doc-number>2002136300</doc-number><kind>A</kind></document-id></patcit><crossref idref="pcit0001">[0013]</crossref><crossref idref="pcit0007">[0026]</crossref></li>
<li><patcit id="ref-pcit0002" dnum="JP2004000203A"><document-id><country>JP</country><doc-number>2004000203</doc-number><kind>A</kind></document-id></patcit><crossref idref="pcit0002">[0015]</crossref><crossref idref="pcit0008">[0026]</crossref></li>
<li><patcit id="ref-pcit0003" dnum="JP2008173127A"><document-id><country>JP</country><doc-number>2008173127</doc-number><kind>A</kind></document-id></patcit><crossref idref="pcit0003">[0017]</crossref><crossref idref="pcit0009">[0026]</crossref></li>
<li><patcit id="ref-pcit0004" dnum="JP2012513215W" dnum-type="L"><document-id><country>JP</country><doc-number>2012513215</doc-number><kind>W</kind></document-id></patcit><crossref idref="pcit0004">[0020]</crossref><crossref idref="pcit0010">[0026]</crossref></li>
<li><patcit id="ref-pcit0005" dnum="EP2787077A1" dnum-type="L"><document-id><country>EP</country><doc-number>2787077</doc-number><kind>A1</kind></document-id></patcit><crossref idref="pcit0005">[0024]</crossref><crossref idref="pcit0012">[0026]</crossref></li>
<li><patcit id="ref-pcit0006" dnum="EP2116614A1" dnum-type="L"><document-id><country>EP</country><doc-number>2116614</doc-number><kind>A1</kind></document-id></patcit><crossref idref="pcit0006">[0025]</crossref><crossref idref="pcit0013">[0026]</crossref></li>
<li><patcit id="ref-pcit0007" dnum="JP4724380B"><document-id><country>JP</country><doc-number>4724380</doc-number><kind>B</kind></document-id></patcit><crossref idref="pcit0011">[0026]</crossref><crossref idref="pcit0014">[0080]</crossref></li>
<li><patcit id="ref-pcit0008" dnum="JP3313358B"><document-id><country>JP</country><doc-number>3313358</doc-number><kind>B</kind></document-id></patcit><crossref idref="pcit0015">[0168]</crossref></li>
<li><patcit id="ref-pcit0009" dnum="JP2015113979A"><document-id><country>JP</country><doc-number>2015113979</doc-number><kind>A</kind><date>20150604</date></document-id></patcit><crossref idref="pcit0016">[0243]</crossref></li>
</ul></p>
<heading id="ref-h0003"><b>Non-patent literature cited in the description</b></heading>
<p id="ref-p0003" num="">
<ul id="ref-ul0002" list-style="bullet">
<li><nplcit id="ref-ncit0001" npl-type="s"><article><author><name>IEVEN</name></author><atl/><serial><sertitle>The Journal Of Infectious Diseases</sertitle><pubdate><sdate>19960000</sdate><edate/></pubdate><vid>173</vid></serial><location><pp><ppf>1445</ppf><ppl>52</ppl></pp></location></article></nplcit><crossref idref="ncit0001">[0065]</crossref></li>
</ul></p>
</ep-reference-list>
</ep-patent-document>
